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Abstract 
Globally, we are seeing an increasing rate of melanoma while melanoma mortality is 
reducing. This is significant as more patients with cancers including melanoma are 
now surviving longer, which increases their risk of being diagnosed with subsequent 
melanomas. In chapter 2, we examined patients with multiple invasive melanomas, 
looking at their pattern of progression towards sentinel node metastasis. 651 patients 
with primary invasive cutaneous melanoma who were referred to the Princess 
Alexandra Hospital melanoma clinic and underwent sentinel lymph node biopsy 
between 1994 and 2011 were included in this study. Information on their index 
melanoma as well as any melanomas before and after were collected and analysed. 
Logistic regression model was used to determine which factors predicted sentinel 
node metastasis. Additional stage II melanoma was an independent and significant 
predictor of sentinel lymph node metastasis. When we evaluated melanoma-specific 
survival in this cohort, patients with additional stage I melanoma had better 
melanoma-specific survival, whereas additional stage II and stage II melanoma prior 
to index melanoma had poorer melanoma-specific survival as expected. Patients 
with additional invasive melanomas fare poorer compared to those with single 
invasive melanoma, especially if the additional melanoma is of a later stage. This 
highlights the importance of patient education in the melanoma survivor population, 
as well as closer surveillance to diagnose any subsequent melanomas at an early 
stage.  
 
Next, we explored the role of various biomarkers using immunohistochemistry, 
including P-STAT5 (phosphorylated signal transducer and activator of transcription 
5) and a panel comprising SOX18 (SRY-related HMG-box 18), Ki67, CD31, D2-40, 
in predicting melanoma outcome in a cohort of clinical stage I and II melanoma 
patients. Identifying novel prognostic biomarkers in locally invasive melanomas to 
predict clinical outcomes is crucial with the new possibilities in adjuvant therapy. It 
enables further stratification of patients to reserve adjuvant therapy to high risk 
patients, provide closer follow up to improve survival, while preventing unnecessary 
exposure of low risk patients to toxicity from adjuvant therapy. 
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We studied cytokine receptor signalling via P-STAT5 to reflect tumour immune 
function as a potential prognostic marker of melanoma. We studied a cohort of stage 
Ib and II melanoma patients, with 189 melanoma tissue samples being analysed for 
active P-STAT5 level by immunohistochemistry and correlated this with patient and 
tumour characteristics and survival outcomes after an average of 10 years of follow-
up. High P-STAT5 level was associated with poor prognostic factors of ulceration 
and increased tumour thickness. However, it was found to be independently and 
inversely associated with melanoma-specific death to 10 years (HR=0.25 [0.07-0.87] 
p=0.029). P-STAT5 allows to identify a subset of patients that have better melanoma 
outcomes despite having poor clinicopathological characteristics at diagnosis 
possibly through immune system activation. This finding could allow major 
improvements in stratification of the risk of progression.  
 
Melanoma progression and metastasis via the vascular and lymphatic channels 
results in extremely poor prognosis. We evaluated the expression of biomarkers 
representing melanoma vascularisation and assessed their association with 
melanoma outcomes including SLN metastasis and melanoma death in a 
prospective cohort. The presence of Ki67+ nuclei in D2-40+ vessels was an 
independent predictor of SLN metastasis and melanoma death, which is a novel 
finding as a combination biomarker in a cohort of melanoma patients. Positive 
SOX18 was associated with lower SLN metastasis and better melanoma-specific 
survival.  
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Chapter 1: 
Introduction and literature review 
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Melanoma epidemiology 
Melanoma is the leading cause of skin cancer-related death primarily due to its 
ability and propensity to metastasize. The incidence of melanoma continues to rise 
globally1, with an increase rate between 1.7-4.8% per year in the United States, 
United Kingdom, Canada, Sweden and Norway.2 In Denmark however, melanoma 
incidence has stabilised since 2011, specifically in those younger than 40 years.2 
More locally, melanoma incidence in New Zealand has decreased 1.3% per year 
since 2008 whereas melanoma incidence in Australia has stabilised since 2002, 
especially in those who are younger than 60 years.2 Despite this stabilisation and 
even decline in melanoma incidence in young Australians age between 15-243, it 
remains as the most common cancer in this age group, accounting for 15% of 
cancers diagnosed4. Melanoma survivors have an increased risk of developing a 
second cancer during their lifetime including melanomas.5 It is projected that 62.5 
per 100 000 males and 42.3 per 100 000 females will be diagnosed with melanoma 
in Australia, making up 15 229 new diagnosis of melanoma in 2019.6  
 
The plateau and decline in melanoma incidence in Australia, Denmark and New 
Zealand could be a result from vigorous sun safety and early detection campaigns 
involving the entire community as well as implementing government policies such as 
tanning bed regulations.7-9 Australia has been a global leader and pioneer in sun 
safety awareness. Public health campaigns since the 1980s such as ‘Slip Slop Slap’, 
‘SunSmart’, and ‘National Skin Cancer Awareness Week’ have proven to be effective 
in educating the public regarding the link between ultraviolet radiation (UVR) 
exposure and skin cancer formation, instilling positive behavioural changes and 
encouraging early skin cancer detection and treatment.10,11 This was reflected in the 
birth cohort pattern of invasive melanoma incidence between 1995-2014 where it 
was stabilising or decreasing in those under 60 years while increasing for those 60 
years and above.12  
 
Melanoma mortality was either stable or decreased in all age groups except men 
who are 60 years and above12, and is projected to account for 1725 deaths in 
Australia in 2019.6 Melanoma mortality and morbidity are typically less favourable in 
rural and regional Australia due to disparities in healthcare access and rural lifestyle, 
with rural patients having 20% higher mortality.13 A way to distribute scarce 
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resources in regional and rural areas would be through better understanding of the 
risk of progression of melanoma patients. In this context, prognostic markers could 
be valuable to further stratify patients, identify those at high risk of progression and 
possibly prompt referral to tertiary centres for initiation of adjuvant therapy. Ideally 
this is a test that could be easily made available in all pathology laboratories 
including those in rural areas, and if successful this could potentially help close the 
mortality gap between rural and urban Australia.  
 
 
Risk factors for melanoma 
Melanoma is a multifactorial disease resulting from interplay between environmental 
factors and genetic predisposition.  
 
Ultraviolet radiation 
The general consensus is that exposure to UVR is the primary modifiable risk factor 
for melanoma, with different patterns of exposure contributing to different level of risk 
and distribution of melanoma.14 In a meta-analysis looking at the association 
between sun exposure and melanoma, history of sunburn was found to have the 
highest risk (RR=2.03), followed by intermittent sun exposure (RR=1.61).15 Chronic 
sun exposure is associated more with actinic keratosis and keratinocyte cancers, 
however is still associated with increased risk melanoma, as described in Whiteman 
et al’s proposal on the divergent pathway model for melanoma development.16 In 
their model, people with low melanocyte proliferation as characterised by low naevi 
counts require chronic sun exposure to induce melanoma and therefore typically 
have more solar damage and develop melanoma on sun-exposed sites. On the other 
hand, people with high naevi counts require sun exposure early on (eg. sunburn in 
childhood or youth) combined with host factors, and typically have less solar damage 
compared to the other group.16 Artificial UV exposure such as tanning bed and 
psoralen-UVA (PUVA) therapy used for treating psoriasis also increase risk of 
melanoma.17-18  
 
Phenotypic characteristics 
In a meta-analysis of 60 observational studies by Gandini et al, phenotypic 
characteristics such as high naevi count (101-120 naevi vs <15, RR=6.89), high 
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atypical naevi count (RR=6.36), hair colour (red vs dark, RR=3.64), skin type (type I 
vs IV, RR=2.09), high freckle count (RR=2.10) and eye colour (blue vs dark, 
RR=1.47) were associated with increased risk of melanoma.19-20 In a Queensland 
prospective cohort study, Olsen et al found self-reported naevus density at age 21 
(many vs no moles, HR=4.91), inability to tan (no tan vs deep tan, HR=3.39), hair 
colour (red vs black, HR=3.11) was associated with higher melanoma risk.21  
 
Family history and personal history 
About 8-12% of melanoma patients have positive family history as defined by one or 
more first-degree relatives with melanoma, which contributes to higher relative risk of 
melanoma (RR=1.74).19 About half of familial melanoma are caused by mutation in 
known high penetrance melanoma genes, the most common being mutations in 
cyclin-dependent kinase inhibitor 2A (CDKN2A).22 Other high penetrance genes 
include cyclin-dependent kinase 4 (CDK4), BRCA1-associated protein-1 (BAP1), 
microphthalmia-associated transcription factor (MITF), telomerase reverse-
transcriptase (TERT), protection of telomeres 1 (POT1), adrenocortical dysplasia 
homologue (ACD) and telomeric repeat binding factor 2, interacting protein 
(TERF2IP).23 Some of these mutations are also linked to other cancers, with 
associations found between CDKN2A (p16) and pancreatic cancer, CDKN2A (p14) 
and neural system tumours, MITF and renal cell carcinoma, POT1 and glioma.23  
 
Similar to family history, having a personal history of melanoma also increases the 
risk of subsequent melanoma. Patients with in-situ or invasive melanoma are more 
likely to have subsequent invasive melanomas, with standardized incidence ratios of 
4.59 and 5.42 respectively.24 The subsequent melanoma was generally located at 
the same body site as initial melanoma.24 Together, these have implications in terms 
of patient surveillance and follow up. 
 
 
Melanoma prognosis  
Upon diagnosis of melanoma, the American Joint Committee on Cancer (AJCC) 
melanoma staging system is the gold standard guideline used internationally to 
stage patients, with the latest 8th edition published in 2017.25  
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Figure 1: AJCC melanoma of the skin staging 8th edition25  
 
 
Patient prognosis is projected based on clinicohistological features of the primary 
tumour such as Breslow thickness, ulceration status, lymph node involvement and 
presence of distant metastasis. Elevated lactate dehydrogenase in the serum 
associated with active metastatic disease is also used as a monitoring tool. One of 
the changes in the 8th edition was removing mitotic rate from the staging criterion for 
T1 melanoma tumours, as review of survival data has shown it was not independent 
of ulceration and tumour thickness as a prognostic factor, and that thin tumours with 
mitotic rate 1/mm2 (T1b) had better prognosis than thicker tumours without mitotic 
figures (T1a).26 Although no longer used to stage thin melanomas, there was still a 
significant correlation between mitotic rate and mortality therefore it was 
 19 
recommended to be included in the pathology report for all tumour regardless of 
thickness. This updated framework includes evidence-based changes from analyses 
carried out on a database of over 46,000 patients from worldwide centres, and in line 
with the evolving scene of Stage IV melanoma treatment. This enables more 
accurate risk stratification, provide better information for clinical trial design and 
analysis, an assist in selecting patients to undergo targeted therapy and 
immunotherapy. 
 
However, there are limitations to the AJCC staging system, for example it does not 
take into account whether or not patients have had multiple melanomas when 
determining their disease stage. The current literature showed multiple melanomas 
led to poorer prognosis, especially when compared to those with single melanoma of 
the same stage or lower.27 Furthermore, there are still significant heterogeneity in 
melanoma survival within each AJCC stage despite the addition of sentinel lymph 
node biopsy (SLNB), which was introduced to address this issue.  
 
Morton et al from the John Wayne Cancer Centre first described SLNB in 1992 as 
part of the staging process for melanoma.28 The sentinel lymph node is the first node 
draining lymph from the primary tumour and is where tumour cells are most likely to 
spread first. SLNB involves targeted surgical removal and histological examination of 
this node and has been widely adopted as a standard of care for staging the regional 
lymph nodes of patients with stage Ib and II primary cutaneous melanoma. SLNB 
has been controversial since its conception and its role and value have been 
debated. While it provides accurate and important staging information that is 
independent of Breslow thickness and ulceration29-30, only a small proportion of high 
risk patients eventually undergo the procedure due logistical reasons and patient 
comorbidities. A Queensland study of high risk melanoma patients showed only 30% 
underwent SLNB.31 Carrying out the procedure requires a facility with appropriate 
and experienced surgical, nuclear medicine and pathology teams. As patients 
typically require general anaesthesia for the procedure, this may not be preferable in 
patients that have surgical and or medical comorbidities.  
 
This highlights the need for a non- or less invasive test that could provide accurate 
information about melanoma prognosis, with less morbidity associated. The optimal 
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sub-staging approach for early stage melanoma remains unanswered. There is a 
need for prognostic tools beyond the current AJCC staging system to improve 
prognostication of early melanomas. The discovery of novel immune and checkpoint 
inhibitor therapies has led to a focus on the role of immune system and immune 
biomarkers in melanoma32. This coupled with a better understanding of tumour 
microenvironment and progression will assist in the discovery of further prognostic 
markers. Melanoma staging will undoubtedly continue to evolve as novel biomarkers 
are discovered and incorporated into clinical practice.   
 
 
Prognostic biomarkers 
Biomarkers are biological molecules found in body tissue or serum that reflect 
normal or abnormal processes, and may inform tumour behaviour, patient prognosis 
and response to treatment. These diagnostic, prognostic or predictive biomarkers 
(Figure 1) are obtained from the primary tumour sample or from a blood test at 
diagnosis, with no invasive tests needed.  
 
Figure 2: Flow chart showing diagnostic, prognostic and predictive tests in 
melanoma management, Foth et al 201633 
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The Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) 
criteria is the gold standard for evaluating and reporting prognostic tumour 
biomarkers.34 It provides a checklist of items (Figure 2) recommended to ensure the 
quality and consistency of these studies.  
 
Figure 3: The REMARK checklist, Altman et al 201235 
 
 
 
Rothberg et al conducted a meta-analysis of 102 published studies on 
immunohistochemistry (IHC) based prognostic protein biomarkers in melanoma and 
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found 37 studies with a total of 62 biomarkers collectively complied with the 
REMARK criteria.36 Among the biomarkers that demonstrated significant association 
with melanoma-specific mortality were p16/INK4a representing insensitivity to 
antigrowth signals (HR=0.4), inducible nitric oxide synthase (iNOS) representing 
sustained angiogenesis (HR=4.63), metallothionein representing limitless replicative 
potential (HR=3.08), and matrix metalloproteinase-2 representing tissue invasion 
and metastasis (HR=2.60).  
 
 
Melanomagenesis and tumour progression 
Development of cancer including melanoma is a complex interplay involving multiple 
pathophysiological steps. Hanahan et al proposed six components that lead to 
malignancy – self-sufficiency in growth signals, insensitivity to antigrowth signals, 
evasion of apoptosis, limitless replicative potential, sustained angiogenesis, and 
tissue invasion and metastasis (Figure 3).37 Melanomagenesis and the its 
subsequent progression involves factors intrinsic to melanoma tumour cells as well 
as the interaction between tumour cells and the host microenvironment.  
 
Figure 4: Acquired capabilities of cancer, Hanahan et al 200037 
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In melanoma, malignant cells go through radial growth phase characterised by 
proliferation within the epidermis, then vertical growth phase whereby they invade 
through the basement membrane into the dermis and finally metastasise when they 
dissociate from the primary tumour and spread via vascular or lymphatic routes to 
distant sites.38-39 Ki67 is a marker of cell proliferation (G1-S phase of cell cycle) and 
one of the most widely studied marker by immunohistochemistry to explore its 
involvement in the metastatic process. Previous studies have shown its prognostic 
value in thin and thick melanomas, where it was significantly associated with 
melanoma-specific mortality and all-cause mortality.40,41,36 Beta3 integrin, an 
adhesion molecule, is associated with the shift from radial to vertical growth phase 
as well as metastatic melanoma, and was shown to have anti-metastatic effect in a 
murine model.42 Of note this molecule is also expressed in Spitz naevi.  
 
There have been cases of spontaneous melanoma regression and simultaneous 
onset of vitiligo indicating immunosurveillance activity in melanoma.43 Furthermore, 
the development of immunotherapy that inhibits the PD-1 (programmed cell death 
protein 1) and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) pathways 
indicate melanoma is an immunogenic tumour and the crucial role the immune 
system plays in the disease.44,45 Realising this, more attention has been given to 
cells in the immune infiltrate in tumour microenvironment, specifically looking at their 
role as potential prognostic or predictive markers. By understanding the immune 
patterns of melanoma, we have the chance to discover immune markers with 
prognostic relevance, new therapeutic targets and predict response of patient to 
specific therapies.   
 
The cutaneous immune system including T-cells, B-cells, natural killer (NK) tcells, 
neutrophils, macrophages, and dendritic cells perform homeostatic function and 
inflammatory responses, but also have shown to facilitate melanomagenesis and 
influence the evolution of tumours.46,47 Pro-tumorigenic and immunosuppressive 
infiltrates from the tumour stroma include CD4+CD25+FOXP3+ regulatory T cells, 
myeloid-derived suppressor cells, M2 macrophages and N2 neutrophils, while NK 
cells, dendritic cells, and CD8+ cytotoxic T lymphocytes are some of the components 
recruited as anti-tumour defense.47 The signal transducer and activator of 
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transcription 5 (STAT5) protein plays a role in T cell activation and proliferation, 
natural killer cell development and Treg induction.48 It is a surrogate of cytokine 
receptor signalling and has been found to be associated with oncogenesis and 
tumour progression.49 
 
Neovascularization and angiogenesis are crucial for tumour survival and metastasis. 
This is reflected in studies targeting antiangiogenic therapy in the field of cancer. 
CD31 (PECAM-1; platelet/endothelial cell adhesion molecule-1) plays a role in 
interaction between adjacent endothelial cells, leukocyte migration, and 
angiogenesis. Previous studies have shown prognostic significance of increased 
vascularity as determined by CD31 staining in intermediate-thickness and metastatic 
melanoma.50-52 Another key regulator of endothelial cell differentiation, angiogenesis 
and lymphangiogenesis is the SOX group F transcription factor comprising SOX7, 
SOX17 and SOX18.53 In adults SOX18 expression has been demonstrated in 
specific settings such as wound healing and tumour growth.54 
 
Lymphovascular biomarkers are of interest as tumours can produce 
lymphangiogenic growth factors that promote formation of new lymphatic vessels, 
tumour cell adhesion and transmigration into vascular spaces which results in 
metastasis. Antibodies specific to lymphatic vessels such as D2-40, 
lymphangiogenetic markers such as vascular endothelial growth factor receptor 3 
(VEGFR3), vascular endothelial growth factor-C (VEGF-C) and vascular endothelial 
growth factor-D (VEGF-D) together with proliferation marker (Ki67) have enabled 
detection of lymphovascular invasion, lymphatic vessel density and 
lymphangiogenesis. Pasquali et al conducted a systematic review of expression of 
lymphangiogenic markers in melanoma tumours.55 They have similar findings to 
Rothberg et al36 in terms of heterogeneous findings, wide methodologic variations 
and poor adherence to either the REMARK criteria or the First International 
Consensus on the Methodology of Lymphangiogenesis Quantification in Solid 
Human Tumours by Van Der Auwera et al56. Of note, the consensus by Van Der 
Auwera et al recommended double immunostaining with D2-40 and Ki67 monoclonal 
antibodies to better detect proliferating lymphatic vessel cells reflecting 
lymphangiogenesis, which has not been carried out in any studies in the existing 
literature. Lymphatic vessel density (LVD) especially in the peritumoral region and 
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lymphatic vessel invasion predicted sentinel lymph node metastasis and melanoma-
specific mortality.55 Intratumoral lymphovasular invasion (LVI) as detected by D2-40 
was found to be an independent predictor of worse disease-free and overall 
survival.55  
 
It is evident that we are still in need of novel prognostic markers or factors that can 
be translated into clinical application to improve melanoma patient stratification. 
Understanding tumour biology and its microenvironment has provided insight into 
melanoma progression and outcome. My study was designed to investigate potential 
clinical and prognostic markers in a cohort of melanoma patients.  
 
  
 26 
Hypotheses 
• Patients with multiple primary melanomas are at higher risk of sentinel lymph 
node invasion.  
• P-STAT5 expression reflects tumour immune function and correlates with 
better melanoma survival.  
• Melanoma vascularisation can predict patient outcome. 
 
 
Aims 
• To investigate effects of a previous diagnosis of invasive melanoma on 
sentinel node metastasis of a subsequent invasive melanoma.  
• To assess activation of cytokine receptor signalling through activity of P-
STAT5 and evaluate its association with melanoma survival and recurrence.  
• To assess prognostic value of lymphovascular biomarkers in terms of SLN 
metastasis and melanoma-specific survival. 
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Chapter 2: 
The pattern of progression of multiple invasive 
melanomas in a Queensland cohort 
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Introduction 
Patients with a diagnosis of melanoma are at increased likelihood of having 
subsequent melanomas in their lifetime, both in-situ or invasive. This risk remains 
elevated for up to 20 years after diagnosis of the first melanoma.5,57-60 In Australia, 
patients diagnosed with their first invasive melanoma have a 6- to 7-fold higher risk of 
a subsequent invasive melanoma compared to the general population.5,24 This has 
become increasingly important as there are growing numbers of melanoma survivors 
in part due to earlier detection and improved treatment.61 
 
The presence of an additional in-situ melanoma in patients with primary invasive 
melanoma, whether preceding, synchronous or subsequent, has been shown not to 
affect survival.58 There have been conflicting findings with regards to survival in 
patients with multiple primary invasive melanomas, with previous studies showing it 
led to poorer, better or no change in prognosis versus single primary invasive 
melanomas.27,62-66 Using delayed entry or time varying entry analysis, we and others 
have shown that once the survival bias is taken into account patients with multiple 
melanomas had poorer survival.27 Of importance, this was only true for multiple 
melanomas of the same stage as compared to a single melanoma of the same stage.27 
 
The mechanism by which an additional invasive melanoma affects survival remains 
unclear. In the present study, we looked at survival of patients with clinical stage Ib 
and II melanoma who have undergone sentinel lymph node (SLN) biopsy and asked 
if patients with multiple primary melanomas were at higher risk of SLN invasion and 
had a peculiar pattern of progression.  
 
 
Methods 
787 patients with primary invasive cutaneous melanoma who were referred to the 
Princess Alexandra Hospital melanoma clinic between 1994 and 2011 were 
considered for inclusion in this study. The eligibility criteria include being at least 18 
years of age and able to provide consent, a diagnosis of clinical stage Ib and II 
melanoma and proceeded to have a SLN biopsy. We excluded patients where no 
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follow up data was available on the Queensland Cancer Registry as they were 
diagnosed in neighbouring states (n=82), patients under 18 years of age at time of 
diagnosis (n=10), patients with missing details or incompatible coding for tumour 
characteristics (n=44). 651 patients were included in the study cohort after written 
consent according to ethics protocol (HREC/09/QPAH/217) of Metro South Human 
Research Ethics Committee. 
 
Study on a large population-based cohort in Queensland by Youlden et al58 found 
that in patients with invasive melanoma, having a preceding, synchronous or 
subsequent in-situ melanoma did not contribute to significant differences in 10-year 
cause-specific mortality. Therefore, we chose to limit our study to only those with 
multiple invasive melanomas. 
 
Patient demographics and clinicohistological characteristics of the index melanoma 
including sex, age at diagnosis, Breslow thickness, ulceration, histological subtype, 
tumour site, SLN status, recurrence and date of diagnosis were prospectively collected 
during visits at the Princess Alexandra Hospital melanoma unit clinic. Index melanoma 
was defined as the melanoma that led to the SLN biopsy, therefore excluding any 
melanomas diagnosed prior to or subsequent to this. Data on presence of additional 
melanomas before or after the index melanoma and their staging and update on 
survival status and date of death (when applicable) up to 31 December 2014 were 
obtained from the Queensland Cancer Registry. These were the latest validated data 
available for release from the Queensland Cancer Registry at the time of request. 
 
Cohort characteristics and clinicohistological features of index tumour were analysed 
for association with additional invasive melanomas and SLN invasion using t-test and 
chi-squared test. Logistical regression model was used to determine predictors of SLN 
invasion. The Cox proportional hazards model was used to determine which 
demographic and tumour characteristics influenced the melanoma-specific mortality 
of patients. Survival interval was calculated from the time of diagnosis of the 
melanoma considered for the sentinel node biopsy to date of melanoma death, date 
of non-melanoma death, or date of last follow up (31 December 2014), whichever 
occurred first. We also included additional invasive melanoma prior to index 
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melanoma, additional stage I and stage II melanoma prior to index melanoma as 
covariates. All data were analysed using IBM SPSS Statistics (Version 25).  
 
 
Results 
Cohort characteristics 
The characteristics of our cohort (n=651) at diagnosis of index melanoma are 
presented in Table 1. The cohort was stratified into those with single invasive 
melanoma (n=566, 86.9%), additional invasive melanoma (n=85, 13.1%), and within 
this, those with additional stage I melanoma (n=79, 12.1%) or additional stage II 
melanoma (n=11, 1.7%), with some overlap between the two groups. For those with 
multiple melanomas, only the information of index melanoma (melanoma that 
warranted the SLN biopsy) are listed in Table 1.  
 
Out of 651 patients, 361 (55.5%) were males and 290 (44.5%) females. With an 
average age at diagnosis of 49 years, our study cohort was younger when compared 
to melanoma patients in the general Queensland population, as all of them had elected 
to undergo SLN biopsy. The average Breslow thickness of the study cohort was 
2.3mm. 170 (26.1%) patients had tumour ulceration, and the main tumour subtype 
was superficial spreading melanoma (60.3%). The highest distribution of tumour site 
was the trunk (35.2%), followed by lower limb (29.6%), upper limb (28.6%) and head 
and neck (6.6%). 92 (14.1%) patients had positive SLN.  85 (13.1%) patients had an 
additional invasive melanoma, of which 36 (5.5%) were diagnosed prior to the index 
melanoma. 79 (12.1%) patients had an additional stage I melanoma, with 31 
diagnosed prior to the index melanoma, and 11 (1.7%) patients had an additional 
stage II melanoma, of which 5 were diagnosed prior to the index melanoma (Table 1).  
  
Table 1: Clinicohistological characteristics of index melanoma of the entire cohort 
and those with single versus multiple invasive melanomas 
 
   Multiple invasive melanomas  
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Total 
cohort 
(n=651) 
n (%) 
Single 
invasive 
melanoma 
(n = 566) 
n (%) 
Additional 
invasive 
melanoma 
(n = 85) 
n (%) 
Additional 
stage I 
melanoma 
(n = 79) 
n (%) 
Additional 
stage II 
melanoma 
(n = 11) 
n (%) 
 
 
 
p-
value 
Sex       
Male 361 
(55.5) 
308 (54.4) 53 (62.4) 49 (62) 8 (72.7) 0.245 
Female 290 
(44.5) 
258 (45.6) 32 (37.6) 30 (38) 3 (27.3)  
Age at 
diagnosis 
      
Mean  SD 49  14 48  14 54  14 53  14 59  14 0.022 
Breslow 
thickness  
      
Mean (mm)  
SD 
2.3  1.6 2.3  1.6 2.5  1.6 2.3  1.1 3.6  3.3 0.227 
Ulceration       
Yes 170 
(26.1) 
147 (26) 23 (27.1) 22 (27.8) 3 (27.3) 0.930 
No 481 
(73.9) 
419 (74) 62 (72.9) 57 (72.2) 8 (72.7)  
Tumour site       
Head & neck 43 (6.6) 34 (6) 9 (10.6) 5 (6.3) 4 (36.4) 0.001 
Trunk 229 
(35.2) 
202 (35.7) 27 (31.8) 27 (34.2) 2 (18.2)  
Upper limb 186 
(28.6) 
161 (28.4) 25 (29.4) 24 (30.4) 3 (27.3)  
Lower limb 193 
(29.6) 
169 (29.9) 24 (28.2) 23 (29.1) 2 (18.2)  
Histology       
SSM 348 
(60.3) 
301 (59.6) 47 (65.3) 45 (65.2) 6 (75) 0.003 
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NM 193 
(33.4) 
175 (34.7) 18 (25) 18 (26.1) 0  
LMM 6 (1) 4 (0.8) 2 (2.8) 1 (1.4) 1 (12.5)  
Desmoplastic 30 (5.2) 25 (5) 5 (6.9) 5 (7.2) 1 (12.5)  
SLN status       
Positive 92 (14.1) 83 (14.7) 9 (10.6) 6 (7.6) 4 (36.4) 0.033 
Negative 559 
(85.9) 
483 (85.3) 76 (89.4) 73 (92.4) 7 (63.6)  
Melanoma 
death 
      
Yes 87 (13.4) 75 (13.3) 12 (14.1) 10 (12.7) 3 (27.3) 0.172 
No 564 
(86.6) 
491 (86.7) 73 (85.9) 69 (87.3) 8 (72.7)  
Additional 
melanoma 
      
Before index 
melanoma 
- - 36 (42.4) 31 (39.2) 5 (45.5) - 
After index 
melanoma 
- - 49 (57.6) 48 (60.8) 6 (54.5)  
*For patients with multiple invasive melanomas, only the information of index 
melanoma (melanoma that warranted the SLN biopsy) are listed  
Abbreviations: SD, standard deviation; SSM, superficial spreading melanoma; NM, 
nodular melanoma; LMM, lentigo maligna melanoma; SLN, sentinel lymph node.
 
Association between clinicohistological features with additional melanoma 
diagnosis 
Patients with multiple invasive melanomas, especially additional stage II melanoma 
were older at time of diagnosis and had a higher rate of tumour on head and neck 
sites (Table 1). Age at diagnosis (p=0.022), head and neck tumour site (p=0.001), and 
positive SLN status (p=0.033) were significantly associated with additional stage II 
melanoma (Table 1).  
 
Association with SLN metastasis 
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A key benefit in assessing the sentinel node is the ability to gain understanding of 
the origin of metastatic deposits. We therefore looked at association of multiple 
invasive melanomas with SLN metastasis, with particular interest on those with a 
prior history of invasive melanoma. We found significant association between 
positive SLN and high Breslow thickness (3.0mm vs 2.2mm, p=0.001), ulceration 
(47.8% vs 22.5%, p<0.001), tumours on the trunk (45.7% vs 33.5%, p=0.016) and 
presence of additional stage II melanoma (4.3% vs 1.3%, p=0.033). There was a 
trend in the association with additional stage I melanoma (p=0.075), additional stage 
II melanoma before index melanoma (p=0.096) and nodular melanoma subtype 
(p=0.098) (Table 2). 
 
When performing multivariate analysis using two sets of covariates listed in table 3, 
Breslow thickness, ulceration and additional stage II melanoma (OR=4.70 [1.12-
19.68] p=0.034) remained significant as independent predictors of positive SLN. 
Additional stage II melanoma before index melanoma continued to show a strong 
trend for predicting positive SLN (OR=8.18 [0.47-143.19] p=0.150). 
 
Table 2: The associations between clinicohistological features and sentinel lymph 
node metastasis  
 
 SLN 
Positive 
(n=92) 
n (%) 
Negative 
(n=559) 
n (%) 
p-
value 
Sex    
Male 50 (54.3) 311 (55.6) 0.818 
Female 42 (45.7) 248 (44.4)  
Age at diagnosis    
Mean  SD 48  14 49  14 0.481 
Breslow thickness     
Mean (mm)  SD 3.0 2.1 2.2 1.4 0.001 
Ulceration    
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Yes 44 (47.8) 126 (22.5) <0.001 
No 48 (52.2) 433 (77.5)  
Tumour site    
Head & neck 6 (6.5) 37 (6.6) 0.016 
Trunk 42 (45.7) 187 (33.5)  
Upper limb 14 (15.2) 172 (30.8)  
Lower limb 30 (32.6) 163 (29.2)  
Histology    
SSM 50 (55.6) 298 (61.2) 0.098 
NM 38 (42.2) 155 (31.8)  
LMM 1 (1.1) 5 (1)  
Desmoplastic 1 (1.1) 29 (6)  
Additional invasive melanoma    
Yes 9 (9.8) 76 (13.6) 0.314 
No 83 (90.2) 483 (86.4)  
Additional invasive melanoma 
before index melanoma 
   
Yes 5 (5.4) 31 (5.5) 0.966 
No 87 (94.6) 528 (94.5)  
Additional stage I melanoma    
Yes 6 (6.5) 73 (13.1) 0.075 
No 86 (93.5) 486 (86.9)  
Additional stage II melanoma    
Yes 4 (4.3) 7 (1.3) 0.033 
No 88 (95.7) 552 (98.7)  
Additional stage II melanoma 
before index melanoma 
   
Yes 2 (2.2) 3 (0.5) 0.096 
No 90 (97.8) 556 (99.5)  
 
 
Table 3: Odds ratios and Confident Intervals for SLN metastasis 
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Univariate analysis Multivariate analysis Multivariate analysis 
OR 95% 
CI 
p-
value 
OR 95% 
CI 
p-
value 
OR 95% 
CI 
p-
value 
Sex (Male) 0.95 0.61-
1.48 
0.818 0.89 0.56-
1.41 
0.616    
Age  0.99 0.98-
1.01 
0.480 0.99 0.98-
1.01 
0.276 0.99 0.97-
1.01 
0.214 
Breslow 
thickness 
1.27 1.13-
1.43 
<0.001 1.21 1.06-
1.37 
0.004 1.31 1.13-
1.52 
<0.001 
Ulceration 3.15 2.00-
4.96 
<0.001 2.85 1.78-
4.57 
<0.001 2.33 1.43-
3.79 
0.001 
Site 
(Trunk) 
1.39 0.55-
3.49 
0.490       
Histology 
(NM) 
1.46 0.92-
2.33 
0.109    1.01 0.61-
1.67 
0.983 
Additional 
invasive 
melanoma 
0.69 0.33-
1.43 
0.317       
Additional 
invasive 
melanoma 
before index 
0.98 0.37-
2.59 
0.966       
Additional 
stage I 
melanoma 
0.46 0.20-
1.10 
0.082 0.41 0.16-
1.04 
0.059    
Additional 
stage II 
melanoma 
3.58 1.03-
12.50 
0.045 4.70 1.12-
19.68 
0.034    
Additional 
stage II 
melanoma 
before index 
melanoma 
4.12 0.68-
24.99 
0.124    8.18 0.47-
143.19 
0.150 
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Discussion 
Cutaneous melanoma is a deadly malignancy that occurs worldwide, with 
Queensland having the highest incidence rate globally.67 Patients with a cancer 
diagnosis have a higher likelihood of developing subsequent cancers. Once a person 
has been diagnosed with a primary melanoma, regardless of in-situ or invasive, they 
are at a higher risk of developing further melanomas, with an estimated lifetime risk 
of up to 8.6%.64,68-71 This could be attributed to factors including genetic 
predisposition, aging, impaired immunologic function, environmental and lifestyle 
factors, improved surveillance and follow up, and exposure to iatrogenic risks such 
as radiotherapy.59-61,69  
   
There have been many studies looking at patients with multiple primary melanomas, 
with mixed reports with regards to their outcomes. Diagnosis of an additional invasive 
melanoma has been shown by Youlden et al to increase mortality risk, and the risk 
differs depending on the combination of stages of the melanomas in individual 
patients.27 In their study, patients with two stage I melanomas or two stage II 
melanomas had significantly poorer outcome than those with single melanoma of the 
equivalent stage. They did not see any significant difference in survival for patients 
with a combination of one stage I and one stage II melanomas versus patients with a 
single stage II melanoma. Similarly, when we confined our cohort to those with only 
stage II index melanoma, additional stage I melanoma was not a significant predictor 
of melanoma specific survival.  
 
In our study, those with additional invasive melanoma were more likely males and had 
poorer prognostic features such as older at diagnosis, higher propensity for head and 
neck sites which is consistent with previous studies.59-60,72 The association between 
increased age at diagnosis and additional invasive melanoma is not surprising as it 
suggests increased cumulative UV damage, whereas the association with head and 
neck sites could be due to propensity for head and neck sites to undergo field UV 
damage leading to formation of more invasive melanomas.  
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Previously, the study on multiple primary melanomas have been largely looking at the 
natural history, clinicohistologic characteristics, risk factors and survival outcome, with 
no focus on SLN metastasis. We therefore explored further the relationship between 
multiple invasive melanomas and SLN metastasis. There were significant associations 
between increased Breslow thickness, ulceration and trunk tumour site with SLN 
metastasis. We found additional stage II melanoma to be a significant predictor of SLN 
metastasis, while additional stage II melanoma before index melanoma had an 
increased odds ratio of 8.18 but did not reach significance (p=0.150), probably due to 
a lack of power. One major limitation in our study is the small number of patients 
especially in the category of those with additional stage II melanoma (n=11) and 
additional stage II melanoma before index melanoma (n=5). Further studies with larger 
cohorts to validate our findings would be beneficial. 
 
SLN metastasis is one of the most important prognostic factors in melanoma. Our 
findings are valuable in guiding future staging process, potentially in terms of more 
aggressive SLN surveillance in those with multiple invasive melanomas especially 
multiple stage II melanomas. This also highlights the need for more accurate 
prognostic biomarkers that can be used in conjunction or instead of SLN biopsy in this 
patient population and the general melanoma population.  
 
The effect of an additional invasive melanoma on melanoma-specific mortality was 
also examined (supplementary results). Additional stage I melanoma had better 
outcome, whereas additional stage II and stage II melanoma prior to index melanoma 
had poorer outcome as expected, however these did not reach significance.   
 
The risk of having multiple melanomas not only affect individual patients but is also of 
public health interest in Australia and around the world where there is combination of 
an ageing population and patients diagnosed with melanoma surviving longer. Our 
study validated that having additional stage II melanoma, with higher Breslow 
thickness and ulceration had worse outcomes for patients. Having multiple invasive 
melanomas should be considered as increased risk and factored into individual patient 
prognosis. Better understanding of the risks and pattern of progression of subsequent 
melanomas and a comprehensive surveillance is essential to detect any subsequent 
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melanoma at an early stage. Patient education, especially targeting the cancer 
survivor population is crucial to ensure positive and proactive attitudes towards follow 
up care. 
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Supplementary results 
Survival analysis 
Upon follow up for an average of 8 years, 87 (13.4%) patients died from melanoma. They 
were mostly males (66.7%, p=0.024) with higher Breslow thickness (3.1mm vs 2.2mm, 
p<0.001), ulceration (48.3% vs 22.7%, p<0.001), higher affinity for head and neck tumour 
sites (13.8% vs 5.5%, p=0.001) and higher rate of positive SLN (37.9% vs 10.5%, p<0.001) 
(supplementary table 1). 
 
A summary of the Hazard Ratios (HR) and Confidence Intervals (CI) for all the covariates in 
melanoma-specific survival using cox regression analysis are shown in supplementary table 
2. Sex, Breslow thickness, ulceration, SLN status, head and neck tumour sites were 
significant predictors of melanoma death on univariate analysis. The presence of additional 
stage II and additional stage II melanoma before index melanoma resulted in increased 
hazard ratios but did not reach significance (HR=2.60 [0.82-8.22] p=0.104, HR=2.69 [0.37-
19.31] p=0.326). We did not observe increased hazard in patients with additional stage I 
melanoma (HR=0.87 [0.45-1.69] p=0.685). 
 
On multivariate analysis using two sets of covariates listed in supplementary table 2, 
Breslow thickness, ulceration and sex remained as independent predictors of melanoma 
death, while additional stage II melanoma and additional stage II melanoma before index 
melanoma showed increased hazards but again did not reach significance (HR=2.80 [0.47-
16.60] p=0.257, HR=1.68 [0.17-16.71] p=0.659).     
 
Supplementary table 1: The associations between clinicohistological features and 
melanoma death  
 
  Melanoma death 
 Yes 
(n=87) 
n (%) 
No 
(n=564) 
n (%) 
p-value 
Sex     
Male  58 (66.7) 303 (53.7) 0.024 
Female  29 (33.3) 261 (46.3)  
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Age at diagnosis     
Mean  SD  50 13 49  14 0.538 
Breslow thickness      
Mean (mm)  SD  3.1  2.0 2.2  1.5 <0.001 
Ulceration     
Yes  42 (48.3) 128 (22.7) <0.001 
No  45 (51.7) 436 (77.3)  
Tumour site     
Head & neck  12 (13.8) 31 (5.5) 0.001 
Trunk  39 (44.8) 190 (33.7)  
Upper limb  13 (14.9) 173 (30.7)  
Lower limb  23 (26.4) 170 (30.1)  
Histology     
SSM  49 (58.3) 299 (60.6) 0.134 
NM  34 (40.5) 159 (32.3)  
LMM  0 6 (1.2)  
Desmoplastic  1 (1.2) 29 (5.9)  
SLN status     
Positive  33 (37.9) 59 (10.5) <0.001 
Negative  54 (62.1) 505 (89.5)  
Additional invasive melanoma     
Yes  12 (13.8) 73 (12.9) 0.827 
No  75 (86.2) 491 (87.1)  
Additional invasive melanoma 
before index melanoma 
    
Yes  4 (4.6) 32 (5.7) 0.683 
No  83 (95.4) 532 (94.3)  
Additional stage I melanoma     
Yes  10 (11.5) 69 (12.2) 0.844 
No  77 (88.5) 495 (87.8)  
Additional stage II melanoma     
Yes  3 (3.4) 8 (1.4) 0.172 
No  84 (96.6) 556 (98.6)  
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Additional stage II melanoma 
before index melanoma 
    
Yes  1 (1.1) 4 (0.7) 0.662 
No  86 (98.9) 560 (99.3)  
 
Supplementary table 2: Hazard ratios and Confident Intervals for melanoma-specific survival 
 
 
 
Univariate analysis Multivariate 
analysis 
Multivariate 
analysis 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
HR 95% 
CI 
p-
value 
Sex (Male) 1.70 1.09-
2.66 
0.019 1.52 0.91-
2.53 
0.107 1.71 1.05-
2.77 
0.031 
Age  1.01 0.99-
1.03 
0.242 1.00 0.98-
1.02 
0.891 1.00 0.99-
1.02 
0.754 
Breslow 
thickness 
1.23 1.14-
1.33 
<0.001 1.35 1.16-
1.57 
<0.001    
Ulceration 2.93 1.93-
4.47 
<0.001 2.53 1.53-
4.19 
<0.001 3.18 1.99-
5.07 
<0.001 
SLN status 4.51 2.92-
6.96 
<0.001       
Site (Head and 
neck) 
2.68 1.34-
5.40 
0.006       
Histology (NM) 1.31 0.81-
2.10 
0.275 0.82 0.48-
1.40 
0.463    
Additional invasive 
melanoma 
1.03 0.56-
1.90 
0.915       
Additional invasive 
melanoma before 
index 
0.91 0.34-
2.49 
0.859       
Additional stage I 
melanoma 
0.87 0.45-
1.69 
0.685       
Additional stage II 
melanoma 
2.60 0.82-
8.22 
0.104 2.80 0.47-
16.60 
0.257    
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Additional stage II 
melanoma before 
index melanoma 
2.69 0.37-
19.31 
0.326    1.68 0.17-
16.71 
0.659 
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Chapter 3: 
Activation of cytokine signalling through STAT5 is 
associated with survival in patients with thick or 
ulcerated locally invasive melanomas 
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Introduction 
Melanoma is the fifth most commonly diagnosed cancer in the United States, with an 
estimated 91,270 new cases in 2018.73 Melanoma in its early stage can be cured by 
surgical resection, with survival rate of 95% at 10 years for stage I melanomas.26 However, 
mortality increases dramatically in people with thicker locally invasive melanomas despite 
the initial complete post-surgical remission at diagnosis.26 
 
Using the current American Joint Committee on Cancer (AJCC, 8th edition) melanoma 
staging system, the prognosis of patients with locally invasive melanoma depends on 
tumour thickness and presence of ulceration.26 While this enables classification of locally 
invasive melanomas into stages with broad prognostic prospects, it lacks the ability to 
inform individual patient prognosis and personalize therapy. Indeed, within each TNM 
(tumour, node metastasis) tumour subcategory, a significant proportion of patients will 
progress to metastasis and death from melanoma without being identified in advance. It is 
important to differentiate patients with higher risk of progression immediately upon 
diagnosis to adjust management.  
  
In recent years, the essential role of the immune system in controlling melanoma 
progression and survival has been revealed resulting in the use and efficacy of immune 
checkpoint inhibitors.74-78 Furthermore, past studies have highlighted the importance of the 
immune infiltrate at diagnosis in predicting patient outcome.79 For many years, cytokine 
production has been considered a hallmark of immune cell activity culminating in the use 
of interferon alpha in the treatment of melanoma.80-81 In this study, we reasoned that in 
primary melanoma tumours, an active immune system would result in cytokine production 
such as interferon alpha and gamma. Following stimulation, cytokines receptors activate 
JAKs (janus kinases) that phosphorylate latent STAT proteins in the cytoplasm to 
translocate into the nucleus and regulate transcription of target genes.82 In the family of 
STAT proteins, STAT1, STAT3 and STAT5a & 5b are found to be associated with 
oncogenesis and/or tumour progression.49 We therefore analysed the activation of 
cytokine receptor signalling through the activity of STAT582-83, its downstream effector, and 
evaluated association of its phosphorylated form (P-STAT5) with melanoma recurrence 
and survival in a cohort of patients with locally invasive melanomas.   
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STAT5a and 5b (located on human chromosome 17q11.2) play a major role in regulating 
cell differentiation and growth including peripheral T cell proliferation and cell cycle 
progression, NK cell development, and the maintenance of haematopoietic stem cell 
population.48 Its role in immune function such as T cell activation and Treg induction is 
demonstrated through its involvement in transduction of cytokine receptor signalling of c-
containing cytokines (IL-2, IL-4, IL-7, IL- 9, IL-15, IL-21). STAT signalling impairment has 
been observed in both peripheral T cells from melanoma patients and T cells at tumour 
sites, and this observation increases in frequency in those with more advanced or 
metastatic disease.83 
 
 
 
Materials and Methods 
Ethics statement 
Ethical approval was obtained through the Metro South Health Human Research Ethics 
Committee, Brisbane, Australia to carry out this project. 
 
Study population 
Our study was carried out and evaluated according to the REMARK criteria.35 All adult 
patients with locally invasive cutaneous melanoma who subsequently underwent SLN 
biopsy at the Princess Alexandra Hospital, Brisbane, between 1994 and 2007 were 
considered for inclusion in our study. Eligibility criteria include being at least 18 years of 
age and able to provide consent, a diagnosis of clinical stage Ib and II melanoma, 
proceeded to have a SLN biopsy, accessible melanoma tissue in the form of whole-section 
slides or formalin-fixed, paraffin embedded tissue blocks. 189 patients were included in the 
study. Each haematoxylin and eosin-stained melanoma tissue slide was reviewed by a 
pathologist to confirm the diagnosis.  
 
Clinicopathological data including age, sex, date of diagnosis, site, tumour thickness, 
ulceration were collected up to 2007, and follow-up data on recurrence and survival were 
collected up to 31 December 2014. These were the latest validated data available for 
release from the Queensland Cancer Registry at the time of request. There was an 
exception of 17 patients who were followed up until February 2013 as their follow-up data 
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beyond this date were not available. Additional data on deaths to 2014 were collected 
through the National Death Index.84   
 
Immunohistochemical staining  
Primary melanoma tissues were stained with the primary monoclonal antibody against 
STAT5 phosphorylated at Tyrosine residue 694 (Abcam ab32364, purified rabbit 
monoclonal anti-P-STAT5 (clone: E208) 220µg/ml, dilution 1:150). In addition to P-STAT5 
we also used three previously validated biomarkers: Ki67, p16 and CD16335,85. Ki67, p16 
and CD163 were chosen because they have been previously reported in REMARK 
compliant studies and validated in this same cohort35. Each antibody was matched with 
respective control samples to ensure staining quality and to determine positive and 
negative staining. Full details of the staining protocol are provided in the supplementary 
materials and methods section. 
 
Evaluation of staining 
P-STAT5 counts were performed across multiple high-power fields over each tumour 
section looking at nuclear uptake in melanoma cells (Fig. 1). Manual scoring was 
performed to ensure accuracy due to the state of some of our older melanoma tissue 
samples which did not stain particularly well. The percentage of positive cells on the 
section was recorded. Intensity of staining was also recorded for each tumour (0: none, 1: 
weak, 2: moderate, 3: strong). A staining index was calculated (staining index = intensity 
score x positive cell percentage) for each lesion and the mean (31) was used as a cut-off 
for analysis separating patients between two categories: High P-STAT5 level versus 
others. Evaluation was performed by two dermatopathologists. Differing scores were 
resolved by consensus during subsequent evaluation.    
 
Figure 1:  Photomicrograph depicts immunostaining of a melanoma section with anti-P-
STAT5 antibody (red). As can be seen, P-STAT5 staining is abundant in this sample at 
high density and high intensity with characteristic nuclear staining reflecting the nuclear 
translocation of the STAT5 protein from the cytoplasm upon phosphorylation 
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Statistical analysis  
The P-STAT5 level was tested for association with standard prognostic factors such as 
SLN status and ulceration using chi-square analysis, and Breslow thickness as a 
continuous variable using t-test. 
 
Melanoma-specific survival was calculated from the date of histological diagnosis to date 
of melanoma death or last follow-up. Disease-free survival was determined by time 
between date of histological diagnosis and date of melanoma recurrence or last follow-up.  
 
Using IBM SPSS statistics software version 25, Cox proportional hazards regression 
models were performed adjusting for age at diagnosis, sex, ulceration and Breslow 
thickness to determine the effect of clinicopathological factors and potential biomarkers on 
survival. Sentinel lymph node status was available for all patients but was not included in 
some models to account for scenarios where patients do not undergo SLN biopsy31. The 
Kaplan-Meier method was also used to analyse survival.   
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Results 
Patient Characteristics 
189 patients with primary invasive melanoma diagnosed between 1994 and 2007 who 
were eligible and underwent SLN biopsy were included in the analysis. The study cohort 
was younger compared to melanoma patients in the general Queensland population as all 
patients elected to undergo SLN biopsy as previously detailed85. However, there was no 
difference in terms of sex distribution and general tumour characteristics compared to the 
Queensland melanoma population. The cohort was composed of 55% male patients, with 
a mean age at diagnosis of 51 years and mean tumour thickness of 2.5mm (Table 1). 49 
(25.9%) patients had ulceration. The most common site of melanoma was the trunk 
(38.1%) followed by lower limb (30.7%), upper limb (23.8%), head and neck (7.4%), while 
the most common melanoma subtype was superficial spreading melanoma (59.0%). SLN 
biopsy was performed in all cases and was positive in 33 (17.5%) patients. The average 
follow-up duration was 10 years. The median times to recurrence and death were 5.6  2.9 
years and 8.0  3.8 years respectively. 52 (27.5%) patients had a recurrence and 41 
(21.7%) died from melanoma during the follow-up period.   
 
Table 1: Cohort Characteristics 
 
 Total  
 (n=189) 
 n (%) 
Sex  
   Male 104 (55.0) 
   Female 85 (45.0) 
Age at diagnosis  
   0 – 40 37 (19.6) 
   41 – 60 104 (55.0) 
   61 – 80 48 (25.4) 
   mean ± SD 51.1 ± 13.6 
Breslow thickness  
   0 – 1.0 mm 14 (7.4) 
   1.0 – 2.0 mm 97 (51.3) 
   2.0 – 4.0 mm 53 (28.0) 
 49 
   >4.0 mm 25 (13.2) 
   Mean (mm) ± SD 2.5 ± 1.95 
Ulceration  
   Yes 49 (25.9) 
   No    140 (74.1) 
Site of primary melanoma  
   Head and Neck 14 (7.4) 
   Upper Limb 45 (23.8) 
   Lower Limb 58 (30.7) 
   Trunk 72 (38.1) 
Histology  
   SSM 111 (59.0) 
   NM 54 (28.7) 
   LMM 5 (2.7) 
   Desmoplastic 8 (4.3) 
   Other 10 (5.3) 
SLN status  
   Positive 33 (17.5) 
   Negative 156 (82.5) 
Biomarker positivity#  
   P-STAT5 28 (15.2) 
   Ki67 28 (15.2) 
   p16 90 (48.1) 
   CD163 73 (40.6) 
Recurrence  
   Yes 52 (27.5) 
   No 137 (72.5) 
Melanoma death  
   Yes 41 (21.7) 
   No 148 (78.3) 
#16 unknowns (P-STAT5), 5 unknowns (Ki67), 2 unknowns (p16), 9 unknowns (CD163). 
 
P-STAT5 activation in primary melanomas 
In the cohort, 14.8% (n=28) had a high P-STAT5 level, while 16 patients could not be given 
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a reliable P-STAT5 score due to equivocal staining (Table 2). High P-STAT5 level was 
significantly and positively associated with Breslow thickness (high P-STAT5 mean Breslow: 
3.79mm vs low P-STAT5: 2.36mm, t-test, p=0.035) and ulceration (high P-STAT5 ulceration 
rate 53.6% vs low P-STAT5 22.8%, chi square, p=0.001). Moreover, tumours with High P-
STAT5 level tended to display a nodular histological subtype (46.4% vs 26.9%, p=0.056, 
non-significant). Overall, tumours harbouring signs of activated cytokine signalling had 
characteristics of more severe disease as they were thicker and more ulcerated. Of 
significant interest, despite reflecting more severe tumours, P-STAT5 level was not 
significantly associated with melanoma death (p=0.284) or recurrence (p=0.966), however 
it showed a trend for association with melanoma-specific survival on unadjusted Kaplan-
Meier analysis (Figure 2). This prompted us to consider P-STAT5 in multivariate models. 
 
 
Table 2: Association of P-STAT5 levels with patient and tumour characteristics 
 
 High P-STAT5 
(n=28)  
n (%) 
Low P-STAT5 
(n=145) 
n (%) 
 
 
p-value# 
Sex 
Male 
Female 
 
19 (67.9) 
9 (32.1) 
 
77 (53.1) 
68 (46.9) 
 
0.150 
Age 
0-40 
41-60 
61-80 
Mean ± SD 
 
5 (17.9) 
17 (60.7) 
6 (21.4) 
51.0 ± 12.1 
 
32 (22.1) 
75 (51.7) 
38 (26.2) 
51.3 ± 13.8 
 
0.909^ 
 
Breslow thickness 
0 – 1.0 mm 
1.1 – 2.0 mm 
2.1 – 4.0 mm 
>4.0 mm 
Mean ± SD 
 
1 (3.6) 
13 (46.4) 
8 (28.6) 
6 (21.4) 
3.79 ± 3.39 
 
10 (6.9) 
74 (51) 
43 (29.7) 
18 (12.4) 
2.36 ± 1.46 
 
0.035^ 
Ulceration 
Yes 
No 
 
15 (53.6) 
13 (46.4) 
 
33 (22.8) 
112 (77.2) 
 
0.001 
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Histology 
SSM 
NM 
LMM 
Desmoplastic 
Other 
 
11 (39.3) 
13 (46.4) 
1 (3.6) 
3 (10.7) 
0  
 
89 (61.4) 
39 (26.9) 
3 (2.1) 
4 (2.8) 
9 (6.2) 
 
0.056 
Site 
Head and neck 
Upper limb 
Lower limb 
Trunk 
 
2 (7.1) 
8 (28.6) 
10 (35.7) 
8 (28.6) 
 
10 (6.9) 
35 (24.1) 
44 (30.3) 
56 (38.6) 
 
0.790 
SLN status 
Positive 
Negative 
 
7 (25) 
21 (75) 
 
24 (16.6) 
121 (83.4) 
 
0.286 
Recurrence 
Yes 
No 
  
8 (28.6) 
20 (71.4) 
 
42 (29) 
103 (71) 
 
0.966 
Melanoma death 
Yes 
No 
 
4 (14.3) 
24 (85.7) 
 
34 (23.4) 
111 (76.6) 
 
0.284 
 
#Pearson Chi-square test 
^t-test 
 
 
 
 
Figure 2: Unadjusted Kaplan-Meier actuarial curves for melanoma-specific death 
comparing survival of patients with high and low P-STAT5 staining 
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Association with melanoma death 
Head and neck sites (p=0.025) and positive SLN status (p<0.001) were significantly 
associated with melanoma death, whereas Breslow thickness was approaching 
significance (p=0.067) (Table 3).  
 
We tested whether P-STAT5 and three other biomarkers (Ki67, p16, CD163) in the 
primary melanoma would have independent predictive value and hence could improve 
predictive potential if combined. In multivariate model with all four biomarkers (P-STAT5, 
Ki67, p16, CD163) and adjusting for known prognostic indicators (age, sex, ulceration, 
Breslow and SLN status), P-STAT5 was inversely associated with melanoma-specific 
death (HR=0.30 [0.09-1.04] p=0.058), while SLN status was the main factor predicting 
mortality (Table 4A). To account for the fact that in a significant number of cases, patients 
do not undergo SLN biopsy we also conducted a multivariate analysis without adjustment 
for SLN status. In this model, the inverse association between P-STAT5 with melanoma 
death was even stronger and reached significance (HR=0.25 [0.07-0.88] p=0.031), 
whereas Breslow thickness was a significant predictor of melanoma death (HR=1.25 [1.07-
1.45] p=0.004) (Table 4B). 
 
 
 
Table 3: Association between cohort characteristics and melanoma death 
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Melanoma death 
 
 
 
 
p-value# 
Yes 
(n=41) 
n (%) 
No 
(n=148) 
n (%) 
Sex 
Male 
Female 
 
26 (63.4) 
15 (36.6) 
 
78 (52.7) 
70 (47.3) 
 
0.222 
Age 
0-40 
41-60 
61-80 
Mean ± SD 
 
8 (19.5) 
26 (63.4) 
7 (17.1) 
50.0 ± 11.8 
 
32 (21.6) 
75 (50.7) 
41 (27.7) 
51.4 ± 14.0 
 
0.554^ 
Breslow thickness 
0 – 1.0 mm 
1.1 – 2.0 mm 
2.1 – 4.0 mm 
>4.0 mm 
Mean (mm) ± SD 
 
0 
15 (36.6) 
20 (48.8) 
6 (14.6) 
3.0 ± 2.0 
 
14 (9.5) 
82 (55.4) 
33 (22.3) 
19 (12.8) 
2.4 ± 1.9 
 
0.067^ 
Ulceration 
Yes 
No 
 
12 (29.3) 
29 (70.7) 
 
37 (25) 
111 (75) 
 
0.581 
Histology 
SSM 
NM 
LMM 
Desmoplastic 
Other 
 
28 (68.3) 
11 (26.8) 
0 
1 (2.4) 
1 (2.4) 
 
83 (56.5) 
43 (29.3) 
5 (3.4) 
7 (4.8) 
9 (6.1) 
 
0.486 
Site 
Head and neck 
Upper limb 
Lower limb 
Trunk  
 
7 (17.1) 
7 (17.1) 
9 (22) 
18 (43.9) 
 
7 (4.7) 
38 (25.7) 
49 (33.1) 
54 (36.5) 
 
0.025 
SLN status    
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Positive 
Negative 
15 (36.6) 
26 (63.4) 
18 (12.2) 
130 (87.8) 
<0.001 
#Pearson Chi-square test 
^t-test 
 
Table 4A: Multivariate analysis for melanoma-specific death, including all 4 biomarkers 
and SLN status  
 
 
HR 95% CI p-value 
Age 0.99 0.97-1.02 0.624 
Sex 0.51 0.25-1.04 0.065 
Breslow 1.16 0.98-1.37 0.091 
Ulceration 0.62 0.26-1.48 0.284 
SLN 4.84 2.14-10.93 <0.001 
P-STAT5 0.30 0.09-1.04 0.058 
Ki67 1.17 0.46-2.98 0.736 
p16 1.27 0.64-2.53 0.488 
CD163 1.79 0.88-3.64 0.107 
 
Table 4B: Multivariate analysis for melanoma-specific death, including all 4 biomarkers, 
excluding SLN status 
 
 
HR 95% CI p-value 
Age 0.98 0.96-1.01 0.231 
Sex 0.55 0.27-1.10 0.092 
Breslow 1.25 1.07-1.45 0.004 
Ulceration 1.29 0.61-2.73 0.507 
P-STAT5 0.25 0.07-0.88 0.031 
Ki67 1.05 0.42-2.60 0.922 
p16 1.24 0.62-2.47 0.551 
CD163 1.79 0.90-3.54 0.096 
 
Association with melanoma recurrence  
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Breslow thickness (p=0.001), ulceration (p=0.040) and SLN status (p<0.001) were 
significantly associated with melanoma recurrence (Table 5).  
 
When all four biomarkers were fit in the cox proportional hazards regression model with 
clinicopathological covariates listed in Table 6A, P-STAT5 was inversely and significantly 
associated with melanoma recurrence (HR=0.39 [0.15-0.99] p=0.046). Breslow thickness 
(HR=1.16 [1.00-1.34] p=0.045), positive SLN (HR=5.44 [2.59-11.45] p<0.001) and Ki67 
(HR=2.28 [1.14-4.56] p=0.020) were significant predictors of melanoma recurrence (Table 
6A). In the model without SLN, P-STAT5 remained inversely associated with melanoma 
recurrence, but did not reach significance (HR=0.41 [0.17-1.02] p=0.056). Breslow thickness 
(HR=1.25 [1.11-1.42] p<0.001) and Ki67 (HR=2.02 [1.04-3.95] p=0.039) remained as 
significant predictors of melanoma recurrence (Table 6B). 
 
Table 5: Association between cohort characteristics and melanoma recurrence 
 
 Recurrence  
 
 
p-value# 
Yes 
(n=52) 
n (%) 
No 
(n=137) 
n (%) 
Sex 
Male 
Female 
 
29 (55.8) 
23 (44.2) 
 
75 (54.7) 
62 (45.3) 
 
0.899 
Age 
0-40 
41-60 
61-80 
Mean ± SD 
 
8 (15.4) 
31 (59.6) 
13 (25) 
51.8 ± 12.9 
 
31 (22.6) 
71 (51.8) 
35 (25.5) 
50.8 ± 13.8 
 
0.619^ 
Breslow thickness 
0 – 1.0 mm 
1.1 – 2.0 mm 
2.1 – 4.0 mm 
>4.0 mm 
Mean (mm) ± SD 
 
2 (3.8) 
17 (32.7) 
19 (36.5) 
14 (26.9) 
3.4 ± 2.3 
 
12 (8.8) 
80 (58.4) 
34 (24.8) 
11 (8) 
2.2 ± 1.7 
 
0.001^ 
Ulceration    
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Yes 
No 
19 (36.5) 
33 (63.5) 
30 (21.9) 
107 (78.1) 
0.040 
Histology 
SSM 
NM 
LMM 
Desmoplastic 
Other 
 
31 (59.6) 
17 (32.7) 
0 
3 (5.8) 
1 (1.9) 
 
80 (58.8) 
37 (27.2) 
5 (3.7) 
5 (3.7) 
9 (6.6) 
 
0.373 
Site 
Head and neck 
Upper limb 
Lower limb 
Trunk  
 
6 (11.5) 
8 (15.4) 
17 (32.7) 
21 (40.4) 
 
8 (5.8) 
37 (27) 
41 (29.9) 
51 (37.2) 
 
0.263 
SLN status 
Positive 
Negative 
 
21 (40.4) 
31 (59.6) 
 
12 (8.8) 
125 (91.2) 
 
<0.001 
#Pearson Chi-square test 
^t-test 
 
Table 6A: Multivariate analysis for recurrence, including all 4 biomarkers and SLN status 
 
 
HR 95% CI p-value 
Age 1.01 0.98-1.03 0.582 
Sex 0.87 0.47-1.60 0.648 
Breslow 1.16 1.00-1.34 0.045 
Ulceration 0.63 0.30-1.31 0.217 
SLN 5.44 2.59-11.45 <0.001 
P-STAT5 0.39 0.15-0.99 0.046 
Ki67 2.28 1.14-4.56 0.020 
p16 1.33 0.73-2.40 0.352 
CD163 1.76 0.93-3.33 0.084 
 
Table 6B: Multivariate analysis for recurrence, including all 4 biomarkers, excluding SLN 
status 
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HR 95% CI p-value 
Age 1.00 0.98-1.02 0.761 
Sex 0.99 0.54-1.78 0.961 
Breslow 1.25 1.11-1.42 <0.001 
Ulceration 1.40 0.76-2.61 0.284 
P-STAT5 0.41 0.17-1.02 0.056 
Ki67 2.02 1.04-3.95 0.039 
p16 1.28 0.70-2.35 0.418 
CD163 1.60 0.87-2.93 0.132 
 
 
Discussion 
Upon diagnosis of invasive melanoma, often the first question asked by patients is about 
prognosis and management. The AJCC has established clear prognostic factors that allow 
a rapid categorization of patients into large outcome groups. However, for locally invasive 
melanoma that displays no sign of regional or systemic dissemination, within each AJCC 
stage, there remains significant variation in outcome. With continuous improvement of our 
knowledge into the intricate processes of melanomagenesis, its driver mutations, the 
metastatic process, and immune checkpoint proteins regulating the host response, one 
could speculate that advances in terms of prognostication could be within reach. We 
followed 189 patients with locally invasive cutaneous melanoma who underwent sentinel 
node biopsy, collecting clinicopathological data and mortality. Our study demonstrated that 
in spite of a high P-STAT5 level being present in more locally advanced melanoma, it was 
found to be independently and inversely associated with melanoma-specific death and 
recurrence. Furthermore, in combination with biomarkers Ki67, p16, CD163, a high P-
STAT5 level remained strongly protective against melanoma death. 
 
Currently, the main prognostic factors of early stage melanoma are Breslow thickness, 
presence of ulceration, and sentinel lymph node status.86-87 Although SLN biopsy helps in 
further stratifying patients within an AJCC prognostic group, it is an invasive albeit low risk 
operative procedure that comes with logistical difficulties and may not be suitable for some 
patients.  Furthermore, among patients with locally invasive melanoma, some develop 
systemic metastasis despite complete surgical excision and in the absence of SLN 
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invasion. This supports the efforts to use molecular information from the tumour 
microenvironment and host immune response to identify high-risk melanomas.36 
 
Initial studies on STAT5a-/- and STAT5b-/- mice showed marked defects in their immune 
responses.88-89 Pericle et al demonstrated that T and B cells isolated from 
immunocompromised tumour-bearing mice had a significantly decreased level of 
expression of STAT5, and there was a correlation between the decreased STAT5 level 
and tumour growth progression.90 Similarly, Grange et al91 found that activated STAT5 led 
to an increased effector T-cell accumulation in melanoma tumours, increased effector T-
cell activation by tumour antigens and expression of cytolytic factor granzyme B, resulting 
in tumour regression. Indeed, accumulation of P-STAT5 in CD8 T cells and NK cells is an 
important element of a robust anti-tumour response.87  
 
STAT5 also plays a role in other signalling cascades in melanoma such as the scavenger 
receptor class B type I (SCARB1/SR-BI) and transient receptor protein channel 3 
(TRPC3).92-93 SR-BI was found to predict melanoma progression and a knockdown of SR-
BI disrupts the metastasis-associated epithelial-to-mesenchymal transition (EMT) 
phenotype in melanoma, in which STAT5 is an important mediator.93 
 
Of interest, other experimental models have suggested an important role of STAT5 
activation in tumour cell maintenance or progression94 which are contradicted here by our 
human data. Indeed, in a clinical setting, high doses of interferon alpha used as adjuvant 
therapy in melanoma resulted in increased P-STAT5 and a reduction of STAT395. Overall 
our findings are in strong concordance with previously published literature suggesting that 
activation of STAT5 reflects the activation of the immune system in the tumour resulting in 
better outcomes. Similarly, when looking at the genetic determinants of immune response 
in melanoma patients, Poźniak et al96 found the subgroup of patients with stronger immune 
responses had better survival.  
 
Although past studies have indicated the importance of tumour infiltrating lymphocytes8 it 
has been difficult to establish if these cells are active, anergic or exhausted. Our study 
provides us with a new marker of effective immune activation in the tumour. P-STAT5 was 
mostly activated in thick and ulcerated tumours where one would expect a worse outcome. 
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Possibly ulceration despite being indicative of tumour progression allows more immune 
activation that in some cases is favourable. Overall, STAT5 activation strongly predicted 
survival, independently from classical prognostic indicators such as Breslow and 
ulceration. These findings indicate that this marker could be used to subdivide current 
staging groups. Indeed, those at risk of progressing may benefit from adjuvant therapy to 
stimulate their immune system. Our study incorporates immunohistochemical staining, a 
straightforward test routinely carried out at pathology laboratories, therefore this can be 
easily performed on melanoma tissues at time of diagnosis. The use of a phosphor-protein 
as a target may require more standardized tissue processing and it is therefore important 
to prospectively validate these findings or to examine the prognostic value of 
immunostaining of direct targets of STAT5 such as SOCS2 (suppressor of cytokine 
signalling 2) or CISH (chromogenic in-situ hybridization). Further, with the validation of any 
new prognostic marker, there is also prospect of translating that into novel therapeutic 
targets.  
 
In conclusion, activation of STAT5 is a robust criterion highlighting activation of the tumour 
immune system and resulting in improved survival in a well-established and REMARK 
compliant cohort of melanoma patients. This finding opens new avenues in the 
subclassification of stage Ib and II patients for future adjuvant therapies. 
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Supplementary materials and methods 
Staining protocol for P-STAT5 Immunohistochemistry  
Antibody: Abcam ab32364, purified rabbit anti-p-STAT5 (clone: E208) 220ug/ml 
Species reactivity: Human, mouse and rat 
Positive control tissue: skin- normal or carinoma, placental trophoblasts, breast carcinoma  
Positive control block: Multi tissue TMA, placenta or breast carcinoma x2128 
Staining pattern: Nuclear 
• Sections (3-µm) are affixed to Menzel Superfrost Plus adhesive slides and airdried 
overnight at 37OC.  
• Sections are dewaxed and rehydrated through descending graded alcohols to 
phosphate-buffered saline (PBS), pH 7.4, using standard protocol. 
• Transfer to EDTA pH 9.0, and subjected to 20 minutes heat antigen retrieval at 95OC 
using the Biocare Medical decloaking chamber. Completion of the cool down cycle 
remove container of slides and allow to cool for a further 20 minutes before 
transferring back to TBS. 
• Wash in 3 changes of TBS. 
• Endogenous peroxidase activity is blocked by incubating the sections in 3.0% H2O2 
in TBS for 10 minutes. 
• Sections are washed in three changes of TBS for 5 minutes each. 
• Biocare Medical Background Sniper is applied for 30 minutes. 
• Excess Sniper is removed and 10% normal goat serum is applied for 30 minutes.  
• Excess normal serum is decanted from the sections and the primary antibody diluted 
1:150 in Biocare Medical Da Vinci Green applied overnight at room temperature.   
• Sections are washed in three changes of TBS for 5 minutes each, the first buffer 
change containing 0.5% (v/v) Triton X-100. 
• Biocare Medical MACH2 anti-rabbit HRP is applied for 60 minutes at RT. 
• Sections are washed in three changes of TBS for 5 minutes each. 
• Control slide signals are developed in vector NovaRed for 5 minutes.  
• Sections are washed in gently running tap water for 5-10 minutes to remove excess 
chromogen. 
• Sections are lightly counterstained in Mayers’ haematoxylin (program 6), then 
dehydrated through ascending graded alcohols, cleared in xylene, and mounted 
using DePeX or similar.  
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Chapter 4: 
Analysis of lymphovascular biomarkers as prognostic 
marker of melanoma 
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Introduction 
Cutaneous melanoma is a leading cause of cancer death, with a 5-year relative survival 
rate of 98% for patients with localised disease, which decreases dramatically to 23% for 
those with distant metastasis.97 The current melanoma staging criteria based on the AJCC 
staging system takes into account the extent of invasion of the primary tumour, lymph 
node involvement and metastatic spread.26 This system has several limitations as the 
survival outcome of patients within the same AJCC melanoma stage can vary widely, with 
some patients having thick melanoma that survive while others with thin melanoma that 
subsequently develop metastasis and die.  
 
As part of the staging process, SLN biopsy is carried out in selected patient population as 
regional lymph node metastasis is one of the most important prognostic factors in 
melanoma.  Although SLN biopsy has become a gold-standard procedure in melanoma for 
the purpose of staging, guiding treatment and recruitment to clinical trials98-99, it comes 
with some post-operative complications. A recent systematic review demonstrated the 
overall post-operative complication rate for SLN biopsy was 11.3% with infection rates 
between 0.3%-19%.100 In addition, about 15% patients with negative SLN will proceed to 
have disease progression.98 Finally, SLN biopsy cannot be applied widely to all patients 
and in a recent study, only 30% of those with an indication of SLN biopsy underwent the 
procedure.31 This has prompted the efforts to look for other prognostic markers that could 
add value to the current staging system and help further distinguish between aggressive 
and less aggressive forms of melanoma at the time of diagnosis.  
 
Mortality in melanoma is primarily the result of tumour metastasis and this happens 
through invasion of the vascular and lymphatic system, spreading to regional or distant 
lymph nodes and organs. Tumour vascularization and lymphangiongenesis have shown to 
be prognostic indicators for the risk of lymph node metastasis in cutaneous melanoma and 
affect patient outcome and survival.101-105 Previous studies revealed the important roles of 
vascular endothelial growth factor (VEGF), fibroblast growth factor, platelet-derived growth 
factor, angiopoietin and SOX18 transcription factors in angiogenesis and 
lymphangiogenesis, and further studies would offer more prognostic and therapeutic 
potential in the form of anti-angiogenic and vascular-targeting agents.54,106-111 Of particular 
interest is the role of SOX18, which together with SOX7 and SOX17 forms the SOX group 
F transcription factors, key regulators of endothelial cell differentiation, angiogenesis and 
lymphangiogenesis.53  
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SOX18 has been shown in preclinical studies to be expressed at early stages of tumour 
angiogenesis and metastasis.112-115 Mutant forms of SOX18 prevent lymphatic metastasis 
suggesting its importance in this process. However, there have not been studies exploring 
the role of SOX18 in a prospective cohort of melanoma patients.  
 
We aimed to evaluate the expression of lymphovascular markers and to assess the impact 
of these markers on the progression and prognosis of melanoma in a prospective cohort. 
We looked at SOX18 and a previously validated biomarker Ki6785 in the endothelial cells of 
lymphatic and blood vessels as determined by vessels positively stained by CD31 and D2-
40, and studied their association with melanoma outcomes including SLN status and 
melanoma death.  
 
 
Materials and Methods 
Ethics statement 
Ethical approval was obtained through the Metro South Health Human Research Ethics 
Committee, Brisbane, Australia to carry out this project. 
 
Patients 
787 patients with invasive cutaneous melanoma who were referred to the Princess 
Alexandra Hospital melanoma clinic and underwent SLN biopsy between 1994 and 2011 
were considered for inclusion in this study. Eligibility criteria include being at least 18 years 
of age and able to provide consent, a diagnosis of clinical stage Ib and II melanoma, 
proceeded to have a SLN biopsy, and accessible melanoma tissues in the form of whole-
section slides or formalin-fixed, paraffin embedded tissue blocks. Melanoma tissues of 289 
patients were retrieved. 18 patients were excluded due to poor staining while 1 patient was 
excluded as the follow-up information was unavailable, leaving 270 patients in the cohort. 
In a previous study by our group, this cohort has been shown to be equivalent to the 
general population undergoing SLN biopsy and younger than the general population with 
locally invasive melanoma thicker than 2mm.85 All haematoxylin-eosin slides were 
reviewed by a pathologist to confirm the diagnosis. Clinicopathologic characteristics 
including sex, age at diagnosis, melanoma histologic subtype and site, Breslow thickness, 
ulceration, and SLN status were recorded and follow up data were collected until 31 
December 2014 for recurrence and survival. These were the latest validated data available 
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for release from the Queensland Cancer Registry at the time of request. 11 patients were 
followed up until May 2013 and 8 patients until December 2010 as their follow-up data 
beyond this date were not available.  
 
Immunohistochemistry 
To identify lymphatic vessels, blood vessels and proliferating endothelial cells, the 
melanoma tissue samples were prepared according to tyramide-based Vectra protocol and 
stained with the primary monoclonal antibody against previously validated biomarkers D2-
40 (Biocare Medical CM266A, mouse anti-D2-40, dilution 1:800), CD31 (Dako M0823, 
mouse anti-CD31, dilution 1:400), Ki67 (Dako M7240, mouse anti-Ki67, dilution 1:1400), 
and SOX18 (anti-SOX18 Mab, human IgG1, dilution 1:1000). The details of staining 
protocol are provided in the supplementary materials and methods section. Each antibody 
was matched with respective control samples to ensure staining quality and to determine 
positive and negative staining. 
 
Evaluation of staining 
Each slide was scanned first at low (x100) magnification to identify area with highest 
vascularity. The number of vessels stained by CD31 or D2-40 were counted in three high-
power fields (x400) within the area of highest vascularity and the sum for each were 
recorded for each slide. The same was repeated for vessels stained by CD31 or D2-40 
that contains Ki67+ or SOX18+ nuclei. Zero was used as a cutoff to divide the cohort into 
absent and present categories for the following five biomarker combinations: 
CD31+/SOX18+, CD31+/Ki67+, D2-40+/SOX18+, D2-40+/Ki67+, CD31+ Ki67+/D2-
40+Ki67+. In addition, SOX18 positive and negative group was determined by the 
presence or absence of SOX18+ nuclei in both CD31+ and D2-40+ vessels. Scoring was 
performed by 2 people and results were corroborated.  
 
Statistical analysis 
All analysis was performed using IBM SPSS statistics software version 25. Melanoma 
survival was calculated from the date of histological diagnosis to date of melanoma death 
or last follow-up.  
 
Presence of vessels stained by SOX18 was tested for association with standard 
prognostic factors including SLN status and ulceration using chi-square analysis, and t-test 
with Breslow thickness. Univariate and multivariate analyses were performed to determine 
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factors predictive of SLN metastasis and melanoma death. Statistical significance was 
defined by p-value of <0.05. 
 
 
Results 
Cohort characteristics 
Our cohort included 151 (55.9%) men and 119 (44.1%) women, with an average age of 52 
years and average Breslow thickness of 2.4mm. Majority of the melanomas were of the 
superficial spreading (60%) and nodular (31.9%) histological types and occurred most 
frequently on the lower limb (35.6%) followed by trunk (30.4%). 51 (19.2%) patients had 
positive sentinel lymph nodes and 53 (20%) patients had melanoma recurrence. The 
average duration of follow up was 7 years and death from melanoma occurred in 46 
patients (17%). The data are summarised in table 1. 
 
Table 1: Distribution of clinicohistologic characteristics and their relation to presence of 
SOX18+ nuclei in vasculatures 
  
 
Total 
cohort 
(n=270) 
n (%) 
 
SOX18 
Negative 
(n=84) 
n (%) 
Positive 
(n=186) 
n (%) 
 
 
p-value 
Sex 
Male 
Female 
 
151 (55.9) 
119 (44.1) 
 
48 (57.1) 
36 (42.9) 
 
103 (55.4) 
83 (44.6) 
 
0.787 
Age 
Mean ± SD 
 
52 ± 13.6 
 
52 ± 14.4 
 
51 ± 13.3 
 
0.667# 
Breslow thickness 
Mean ± SD 
 
2.4 ± 1.8 
 
2.8 ± 2.1 
 
2.2 ± 1.6 
 
0.022# 
Ulceration* 
Yes 
No 
 
70 (26) 
199 (74) 
 
26 (31) 
58 (69) 
 
44 (23.8) 
141 (76.2) 
 
0.214 
Histology^ 
SSM 
NM 
 
156 (60) 
83 (31.9) 
 
47 (59.5) 
28 (35.4) 
 
109 (60.2) 
55 (30.4) 
 
0.458 
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LMM 
Desmoplastic 
Other 
6 (2.3) 
9 (3.5) 
6 (2.3) 
1 (1.3) 
3 (3.8) 
0 
5 (2.8) 
6 (3.3) 
6 (3.3) 
Site 
Head or neck 
Trunk 
Upper limb 
Lower limb 
 
19 (7) 
82 (30.4) 
73 (27) 
96 (35.6) 
 
6 (7.1) 
21 (25) 
22 (26.2) 
35 (41.7) 
 
13 (7) 
61 (32.8) 
51 (27.4) 
61 (32.8) 
 
0.480 
SLN status** 
Positive 
Negative 
 
51 (19.2) 
214 (80.8) 
 
25 (29.8) 
59 (70.2) 
 
26 (14.4) 
155 (85.6) 
 
0.003 
Recurrence^^ 
Yes 
No 
 
53 (20) 
212 (80) 
 
26 (31) 
58 (69) 
 
27 (14.9) 
154 (85.1) 
 
0.002 
Melanoma death 
Yes 
No 
 
46 (17) 
224 (83) 
 
19 (22.6) 
65 (77.4) 
 
27 (14.5) 
159 (85.5) 
 
0.101 
CD31+Ki67+  
Present 
Absent 
 
59 (21.9) 
211 (78.1) 
 
6 (7.1) 
78 (92.9) 
 
53 (28.5) 
133 (71.5) 
 
<0.001 
D2-40+Ki67+  
Present 
Absent 
 
13 
257 
 
3 (3.6) 
81 (96.4) 
 
10 (5.4) 
176 (94.6) 
 
0.521 
CD31+D2-40+Ki67+  
Present 
Absent 
 
66 (24.4) 
204 (75.6) 
 
8 (9.5) 
76 (90.5) 
 
58 (31.2) 
128 (68.8) 
 
<0.001 
STAT5 
High 
Low 
 
27 (16.3) 
139 (83.7) 
 
13 (19.1) 
55 (80.9) 
 
14 (14.3) 
84 (85.7) 
 
0.407 
CD163 
High  
Low 
 
72 (41.4) 
102 (58.6) 
 
29 (41.4) 
41 (58.6) 
 
43 (41.3) 
61 (58.7) 
 
0.991 
#T-test  *1 unknown   ^10 unknown   **5 unknown   ^^5 unknown  
 
SOX18 distribution in cutaneous melanoma 
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SOX18 staining could be identified in the vasculature and more specifically in endothelial 
or lymphatic endothelial nuclei (Figures 1 & 2). SOX18 positive nuclei seemed to occur 
more frequently in tumour vessels of patients who were alive at the end of the follow-up 
period, compared to those who died from melanoma (mean 2.5 vessels ± 2.8 vs 1.7 
vessels ± 2.0, p=0.017) (Table 2). When comparing patients who displayed any SOX18 
positive nuclei to those with no detectable SOX18, the former had a lower rate of positive 
SLN (14.4% vs 29.8%, p=0.003) and recurrence (14.9% vs 31%, p=0.002) (Table 1). They 
also had better prognostic features such as lower Breslow thickness (2.2 ± 1.6mm vs 2.8 ± 
2.1mm, p=0.022), lower rate of ulceration (23.8% vs 31%, p=0.214), and lower frequency 
of nodular subtype (30.4% vs 35.4%, p=0.458), although the latter two did not reach 
significance (Table 1). Interestingly even though the SOX18 positive group was associated 
with better prognostic features, they were also associated with higher rate of proliferative 
marker in their vasculature as demonstrated by the higher number of CD31+ vessels with 
Ki67+ nuclei (31.2% vs 9.5%, p<0.001) (Table 1). We correlated SOX18 level with immune 
biomarkers previously studied by our group on the same cohort25 and noted those in the 
SOX18 positive group had a similar percentage of high STAT5 staining (14.3% vs 19.1%, 
p=0.407) and CD163 (Table 1). 
 
Figure 1: Staining of anti-SOX18 antibody (red) in vascular (yellow) endothelial cells  
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Figure 2: Staining of anti-SOX18 antibody (red) in lymphatic (cyan) endothelial cell and 
also seen in melanoma (purple) cell nuclei 
 
 
 
Table 2: Univariate analysis of the association with SLN status and melanoma death 
 
 
Variables mean  
(SD) 
SLN status Melanoma death 
Pos 
n=51 
Neg 
n=214 
p-value Yes 
n=46 
No 
n=224 
p-
value 
CD31+ vessels 14.7 
(11.4) 
15.2 
(9.8) 
0.710 14.3 
(10.1) 
15.3 
(10.0) 
0.546 
CD31+ vessels with 
SOX18+ nuclei  
1.6 
(2.1) 
2.4 
(2.6) 
0.037 1.6 
(2.0) 
2.4 
(2.6) 
0.059 
CD31+ vessels with 
Ki67+ nuclei  
0.3 
(0.5) 
0.3 
(0.7) 
0.682 0.3 
(0.6) 
0.3 
(0.7) 
0.784 
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D240+ vessels 7.2 
(4.2) 
6.4 
(4.4) 
0.243 7.6 
(4.7) 
6.4 
(4.2) 
0.080 
D240+ vessels with 
SOX18+ nuclei  
0.1 
(0.5) 
0.2 
(0.5) 
0.335 0.1 
(0.3) 
0.2 
(0.5) 
0.134 
D240+ vessels with 
Ki67+ nuclei  
0.2 
(0.7) 
0  
(0.2) 
0.138 0.2 
(0.6) 
0.1 
(0.3) 
0.305 
All vessels with SOX18+ 
nuclei  
1.7 
(2.4) 
2.6 
(2.8) 
0.033 1.7 
(2.0) 
2.5 
(2.8) 
0.017 
All vessels with Ki67+ 
nuclei  
0.5 
(1.2) 
0.4 
(0.8) 
0.401 0.4 
(1.0) 
0.4 
(0.8) 
0.614 
 
 
Association with SLN status 
Tumour lymphangiogenesis has been linked to SLN metastasis and therefore we 
examined whether the presence of SOX18 and Ki67 in lymphatics and blood vessels can 
be used in predicting SLN status in melanoma patients. We divided the cohort into positive 
and negative SLN groups and expectedly found significant association between positive 
SLN and high Breslow thickness (p=0.002), presence of ulceration (p<0.001), recurrence 
(p<0.001), melanoma death (<0.001), absence of SOX18+ nuclei in CD31+ vessels 
(p=0.005), and absence of SOX18+ nuclei in CD31+ and D2-40+ vessels (p=0.003) (Table 
3). There was a trend in the association between presence of Ki67+ nuclei in D2-40+ 
vessels (p=0.072) and positive SLN (Table 3). 
 
To identify risk factors for developing positive SLN, univariate and multivariate analysis 
were performed. All clinicopathologic characteristics and biomarkers were included in the 
univariate analysis. We found that age, Breslow thickness, ulceration, SOX18+ nuclei in 
CD31+ vessels, SOX18+ nuclei in CD31+ and D2-40+ vessels, Ki67+ nuclei in D2-40+ 
vessels were significant predictors of SLN status (Table 4). 
 
When performing multivariate analysis using covariates listed in table 4, only Breslow 
thickness (OR=1.32 [1.10-1.60] p=0.004), ulceration (OR=5.02 [2.43-10.35] p=<0.001) and 
Ki67+ nuclei in D2-40+ vessels (OR=2.92 [1.26-6.79] p=0.013) were independent 
predictors of positive SLN. SOX18+ nuclei in CD31+ and D2-40+ vessels almost reached 
significance as a negative predictor (OR=0.86 [0.73-1.01] p=0.068).  
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Table 3: Association between clinicohistologic characteristics and SLN status 
 
 Positive SLN 
(n=51) 
n (%) 
Negative SLN 
(n=214) 
n (%) 
 
 
p-value 
Sex 
Male 
Female 
 
34 (66.7) 
17 (33.3) 
 
115 (53.7) 
99 (46.3) 
 
0.094 
Age 
Mean ± SD 
 
48 ± 16.2 
 
52 ± 12.9 
 
0.050# 
Breslow thickness 
Mean ± SD 
 
3.3 ± 2.3 
 
2.2 ± 1.6 
 
0.002# 
Ulceration* 
Yes 
No 
 
27 (54) 
23 (46) 
 
42 (19.6) 
172 (80.4) 
 
<0.001 
Histology^ 
SSM 
NM 
LMM 
Desmoplastic 
Other 
 
28 (54.9) 
22 (43.1) 
0  
1 (2) 
0 
 
125 (61.3) 
59 (28.9) 
6 (2.9) 
8 (3.9) 
6 (2.9) 
 
0.177 
Site 
Head or neck 
Trunk 
Upper limb 
Lower limb 
 
5 (9.8) 
15 (29.4) 
8 (15.7) 
23 (45.1) 
 
13 (6.1) 
66 (30.8) 
64 (29.9) 
71 (33.2) 
 
0.134 
Recurrence 
Yes 
No 
 
24 (47.1) 
27 (52.9) 
 
29 (13.6) 
185 (86.4) 
 
<0.001 
Melanoma death 
Yes 
No 
 
19 (37.3) 
32 (62.7) 
 
27 (12.6) 
187 (87.4) 
 
<0.001 
CD31+SOX18+ 
Present 
 
26 (51) 
 
153 (71.5) 
 
0.005 
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Absent   25 (49) 61 (28.5) 
CD31+Ki67+  
Present 
Absent 
 
12 (23.5) 
39 (76.5) 
 
46 (21.5) 
168 (78.5) 
 
0.752 
D2-40+SOX18+ 
Present 
Absent   
 
3 (5.9) 
48 (94.1) 
 
29 (13.6) 
185 (86.4) 
 
0.131 
D2-40+Ki67+  
Present 
Absent 
 
5 (9.8) 
46 (90.2) 
 
8 (3.7) 
206 (96.3) 
 
0.072 
CD31+D2-40+ SOX18+  
Present 
Absent 
 
26 (51) 
25 (49) 
 
155 (72.4) 
59 (27.6) 
 
0.003 
CD31+D2-40+ Ki67+  
Present 
Absent 
 
13 (25.5) 
38 (74.5) 
 
52 (24.3) 
162 (75.7) 
 
0.859 
#T-test  *1 unknown      ^10 unknown   
 
Table 4: Univariate and multivariate regression analyses of the association with SLN 
metastasis  
 
 Univariate analysis Multivariate analysis 
OR 95% CI p-value OR 95% CI p-value 
Sex 
Male 
 
1.72 
 
0.91-3.27 
 
0.097 
 
1.39 
 
0.67-2.86 
 
0.379 
Age 0.98 0.95-1.00 0.024 0.95 0.93-0.98 0.001 
Breslow thickness 1.33 1.13-1.57 0.001 1.32 1.10-1.60 0.004 
Ulceration 4.81 2.51-9.21 <0.001 5.02 2.43-
10.35 
<0.001 
Histology 
NM 
 
1.67 
 
0.88-3.15 
 
0.118 
   
Site 
Head and neck 
 
1.19 
 
0.38-3.69 
 
0.767 
   
CD31+SOX18+ 0.86 0.74-0.99 0.040    
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CD31+Ki67+  0.91 0.56-1.46 0.681    
D2-40+SOX18+ 0.67 0.30-1.52 0.342    
D2-40+Ki67+  2.28 1.06-4.87 0.034 2.92 1.26-6.79 0.013 
CD31+D2-40+SOX18+  0.86 0.75-0.99 0.037 0.86 0.73-1.01 0.068 
CD31+D2-40+Ki67+  1.15 0.83-1.60 0.403    
 
 
Association with melanoma survival 
The cohort was divided into two groups according to melanoma survival status (Table 5). 
There was significant association between melanoma death and the clinicopathologic 
characteristics Breslow thickness (p=0.020), head and neck site (p=0.009), SLN positivity 
(p<0.001) and recurrence (p<0.001), and they were significant predictors of melanoma 
death in univariate analysis (Table 6). There was an apparent trend in the association 
between melanoma death and absence of SOX18+ nuclei in CD31+ and D2-40+ vessels 
(p=0.101), absence of SOX18+ nuclei in CD31+ vessels (p=0.131) and presence of Ki67+ 
nuclei in D2-40+ vessels (p=0.177) (Table 5).  
 
Multivariate analysis showed only Ki67+ nuclei in D2-40+ vessels was an independent 
predictor of melanoma death (HR=1.71 [1.03-2.83] p=0.037) (Table 6). Of note, in these 
models we did not include SLN status to explore the possibility of our biomarkers to 
replace SLNB. When SLN was included, none of the biomarkers remained independently 
associated with survival (not shown). 
 
Table 5: Association between clinicohistologic characteristics and melanoma survival   
 
 Dead 
(n=46) 
n (%) 
Alive 
(n=224) 
n (%) 
 
 
p-value 
Sex 
Male 
Female 
 
31 (67.4) 
15 (32.6) 
 
120 (53.6) 
104 (46.4) 
 
0.086 
Age 
Mean ± SD 
 
50 ± 12.2 
 
52 ± 13.9 
 
0.347# 
Breslow thickness    
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Mean ± SD 3.0 ± 1.9 2.3 ± 1.7 0.020# 
Ulceration* 
Yes 
No 
 
13 (28.3) 
33 (71.7) 
 
57 (25.6) 
166 (74.4) 
 
0.704 
Histology^ 
SSM 
NM 
LMM 
Desmoplastic 
Other 
 
29 (64.4) 
14 (31.1) 
0 
1 (2.2) 
1 (2.2) 
 
127 (59.1) 
69 (32.1) 
6 (2.8) 
8 (3.7) 
5 (2.3) 
 
0.793 
Site 
Head or neck 
Trunk 
Upper limb 
Lower limb 
 
8 (17.4) 
9 (19.6) 
10 (21.7) 
19 (41.3) 
 
11 (4.9) 
73 (32.6) 
63 (28.1) 
77 (34.4) 
 
0.009 
SLN status** 
Positive 
Negative 
 
19 (41.3) 
27 (58.7) 
 
32 (14.6) 
187 (85.4) 
 
<0.001 
Recurrence^^ 
Yes 
No 
 
35 (76.1) 
11 (23.9) 
 
18 (8.2) 
201 (91.8) 
 
<0.001 
CD31+SOX18+ 
Present 
Absent   
 
27 (58.7) 
19 (41.3) 
 
157 (70.1) 
67 (29.9) 
 
0.131 
 
CD31+Ki67+  
Present 
Absent 
 
10 (21.7) 
36 (78.3) 
 
49 (21.9) 
175 (78.1) 
 
0.984 
 
D2-40+SOX18+ 
Present 
Absent   
 
4 (8.7) 
42 (91.3) 
 
28 (12.5) 
196 (87.5) 
 
0.467 
D2-40+Ki67+  
Present 
Absent 
 
4 (8.7) 
42 (91.3) 
 
9 (4) 
215 (96) 
 
0.177 
CD31+D2-40+ SOX18+     
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Present 
Absent 
27 (58.7) 
19 (41.3) 
159 (71) 
65 (29) 
0.101 
CD31+D2-40+ Ki67+  
Present 
Absent 
 
11 (23.9) 
35 (76.1) 
 
55 (24.6) 
169 (75.4) 
 
0.927 
#T-test      *1 unknown     ^10 unknown **5 unknown     ^^5 unknown 
 
Table 6: Univariate and multivariate regression analyses of the association with 
melanoma-specific death 
 
 Univariate analysis Multivariate analysis 
HR 95% CI p-value HR 95% CI p-value 
Sex 
Male 
 
1.76 
 
0.95-3.25 
 
0.074 
 
1.66 
 
0.89-3.12 
 
0.115 
Age 1.00 0.98-1.02 0.708 0.99 0.97-1.01 0.374 
Breslow thickness 1.14 1.02-1.27 0.019 1.11 0.99-1.25 0.069 
Ulceration 1.13 0.59-2.15 0.714 0.97 0.50-1.87 0.923 
Histology 
NM 
 
0.97 
 
0.51-1.84 
 
0.928 
   
Site 
Head and neck 
 
2.37 
 
1.03-5.42 
 
0.042 
   
SLN  3.82 2.12-6.88 <0.001    
Recurrence 18.80 9.51-37.18 <0.001    
CD31+SOX18+ 0.89 0.77-1.02 0.100    
CD31+Ki67+  0.96 0.61-1.50 0.855    
D2-40+SOX18+ 0.67 0.28-1.58 0.362    
D2-40+Ki67+  1.64 1.00-2.71 0.051 1.71 1.03-2.83 0.037 
CD31+D2-40+SOX18+  0.89 0.78-1.02 0.090 0.90 0.78-1.03 0.111 
CD31+D2-40+Ki67+  1.11 0.81-1.54 0.514    
 
Association with melanoma outcome in SLN negative cohort 
Despite its benefits, SLNB does not capture all melanoma related events and a significant 
number of patients die from the disease. We therefore examined SLN negative cohort only 
and performed statistical analysis for melanoma survival. Breslow thickness (p=0.032), 
head and neck site (p=0.038) and recurrence (p<0.001) were significantly associated with 
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melanoma death (Table 7). In univariate analysis, only D2-40+ vessel was a significant 
predictor of melanoma death and it remained significant in multivariate analysis (HR=1.10 
[1.01-1.19] p=0.025) (Table 8). 
 
Table 7: Association between clinicopathologic characteristics and biomarkers with 
melanoma survival in SLN negative cohort  
 
 Dead  
(n=27)  
n (%) 
Alive  
(n=187) 
n (%) 
 
 
p-value 
Sex 
Male 
Female 
 
17 (63) 
10 (37) 
 
98 (52.4) 
89 (47.6) 
 
0.304 
Age 
Mean ± SD 
 
53 ± 11.7 
 
52 ± 13.1 
 
0.317# 
Breslow thickness 
Mean ± SD 
 
2.5 ± 1.2 
 
2.2 ± 1.6 
 
0.032# 
Ulceration 
Yes 
No 
 
5 (18.5) 
22 (81.5) 
 
37 (19.8) 
150 (80.2) 
 
0.877 
Histology* 
SSM 
NM 
LMM 
Desmoplastic 
Other 
 
18 (69.2) 
6 (23.1) 
0 
1 (3.8) 
1 (3.8) 
 
107 (60.1) 
53 (29.8) 
6 (3.4) 
7 (3.9) 
5 (2.8) 
 
0.805 
Site 
Head or neck 
Trunk 
Upper limb 
Lower limb 
 
4 (14.8) 
3 (11.1) 
9 (33.3) 
11 (40.7) 
 
9 (4.8) 
63 (33.7) 
55 (29.4) 
60 (32.1) 
 
0.038 
Recurrence 
Yes 
No 
 
20 (74.1) 
7 (25.9) 
 
9 (4.8) 
178 (95.2) 
 
<0.001 
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All CD31vessel_w_SOX18nuclei  
Present 
Absent 
 
19 (70.4) 
8 (29.6) 
 
134 (71.7) 
53 (28.3) 
 
0.890 
All CD31vessel_w_Ki67nuclei  
Present 
Absent 
 
5 (18.5) 
22 (81.5) 
 
41 (21.9) 
146 (78.1) 
 
0.687 
All D240vessel_w_SOX18nuclei  
Present 
Absent 
 
3 (11.1) 
24 (88.9) 
 
26 (13.9) 
161 (86.1) 
 
0.692 
All D240vessel_w_Ki67nuclei  
Present 
Absent 
 
1 (3.7) 
26 (96.3) 
 
7 (3.7) 
180 (96.3) 
 
0.992 
All_vessels_w_SOX18nuclei  
Present 
Absent 
 
19 (70.4) 
8 (29.6) 
 
136 (72.7) 
51 (27.3) 
 
0.798 
All_vessels_w_Ki67nuclei  
Present 
Absent 
 
5 (18.5) 
22 (81.5) 
 
47 (25.1) 
140 (74.9) 
 
0.454 
#T-test  *10 unknown  
 
Table 8: Univariate and multivariate regression analyses in SLN negative cohort for 
melanoma-specific death 
 
 Univariate analysis Multivariate analysis 
HR 95% CI p-value HR 95% CI p-value 
Sex 1.48 0.68-3.23 0.329 1.43 0.65-3.17 0.376 
Age 1.01 0.98-1.04 0.686 1.00 0.97-1.04 0.815 
Breslow 1.10 0.93-1.30 0.282 1.03 0.85-1.25 0.752 
Ulceration 0.97 0.37-2.57 0.957 0.86 0.32-2.29 0.756 
Histology 
NM 
 
0.76 
 
0.30-1.91 
 
0.557 
 
 
  
Site 
Head and neck 
 
1.94 
 
0.62-6.09 
 
0.259 
   
CD31+ 1.01 0.97-1.05 0.693    
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CD31+SOX18+  0.91 0.77-1.08 0.287    
CD31+Ki67+  0.90 0.50-1.63 0.724    
D240+ 1.09 1.01-1.18 0.030 1.10 1.01-1.19 0.025 
D240+SOX18+  0.78 0.29-2.11 0.627    
D240+Ki67+  0.84 0.13-5.39 0.857 0.78 0-12-4.95 0.795 
CD31+D2-40+SOX18+ 0.91 0.78-1.08 0.278 0.91 0.77-1.07 0.237 
CD31+D2-40+Ki67+  0.90 0.51-1.57 0.700    
 
Discussion 
Cutaneous melanoma is the most aggressive and deadly form of skin cancer, causing 
80% of skin cancer deaths even though it represents less than 5% of all skin cancers.116 
Over the last two decades, there has been significant increase in education and 
awareness leading to risk reduction, prevention and early detection of melanoma. More 
recently, discovery of melanoma genetics, targeted therapy and immunotherapy have 
improved patient survival.74-75 However, these adjuvant therapies come with their own 
toxicities and adverse effects. Therefore, it is important to be able to further stratify 
patients within the same AJCC stage beyond our current capabilities, and identify the ones 
with aggressive melanoma at the time of diagnosis to appropriately undergo adjuvant 
treatment. Currently adjuvant therapy decision is made mainly based on sentinel node 
status. 
 
Lymphatic vasculature has emerged to play a key role in regional lymph node and distant 
metastasises. Key routes of spreading to regional and distant lymph nodes include direct 
invasion of existing lymphatic vessels by tumour cells or via lymphangiogenesis induced 
by the tumour itself through expression of various transcription or growth factors such as 
SOX18 and VEGF.104-105,117 Lymphatic vessel density have also been associated with 
nodal metastasis.117 We included D2-40 in our biomarker panel as it is an endothelial 
marker highly specific for lymphatics and has been shown to be more effective in detecting 
lymphatic invasion compared to conventional haematoxylin and eosin staining.103,118-119 
D2-40 has been utilised to highlight lymphatic vessel invasion in melanoma as well as 
other cancers such as breast, oesophageal and endometrial cancers.120-122 
 
Our panel of protein biomarker also included SOX18, a transcription factor involved in the 
development of embryonic vascular and lymphatic vessels and hair follicles.54 
Consequently, a disruption in SOX18 expression has been demonstrated in hypotrichosis-
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lymphoedema-telangiectasia syndrome, characterized by hair loss, swelling of the 
extremities due to lymphatic vessel leakage and widening of small blood vessels.123 In 
adults, SOX18 expression has been demonstrated in specific settings such as wound 
healing and tumour growth, whereby it is seen in endothelial nuclei and tumour cell 
nuclei.54 SOX18 is involved in increased endothelial cell migration and fusion. It activates 
endothelial cells through the PROX-1 (Prospero Homeobox 1) and VEGF-Flk1 pathway, 
activates VCAM1 (vascular cell adhesion molecule 1) expression required for endothelial 
cell function, and interacts with MEF2C (myocyte enhancer factor 2C), a muscle and 
endothelial transcription factor.115,117,124,125 SOX18 expression has been observed in 
different types of cancers including melanoma, non-melanoma skin cancers, lung cancer 
and breast cancer.113,126-129 Overman et al130 found that supressing SOX18 activity 
interfered with vascular development and improved survival in an animal model of breast 
cancer by reducing vascular density and reducing metastatic spread. Duong et al113 had 
similar findings where SOX18-mutant mice had a lower rate of lymphangiogenesis and 
metastasis. 
 
In this study, we found that patients with SOX18 in their vasculature had better prognostic 
features such as lower Breslow thickness (p=0.022), lower rate of positive SLN (p=0.003) 
and recurrence (p=0.002). One theory for the different findings compared to existing 
literature is that SOX18 expression increased angiogenesis and lymphangiogenesis, 
resulting in increased migration of immune cells to tumour and lymph node sites, inhibiting 
tumour growth and subsequently led to better outcomes. To explore if SOX18 plays a role 
in tumour immune function, we examined the association between SOX18 and immune 
markers including STAT5 and CD163 and found no significant associations (Table 1), 
although we only had information on STAT5 staining for 166 patients and CD163 staining 
for 174 patients. Correlation with other immune markers would be beneficial to further 
explore this theory. Another theory is that the SOX18 expression seen is largely from 
mature endothelial cells, that is the definitive differentiated population rather than the 
endovascular progenitor population that has self-renewal and proliferative potential. 112,131 
This is based on the findings from our group that endothelial cells have distinct hierarchal 
populations with different function - endovascular progenitor, transit amplifying and 
definitive differentiated populations. 112,131 
 
On multivariate analysis, the presence of Ki67+ nuclei in D2-40+ vessels was an 
independent predictor of SLN metastasis and melanoma death. This is consistent with the 
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existing literature on Ki67, a proliferation marker that has been previously studied as a 
potential biomarker of melanoma progression.36,40,132 Ki67 is associate with poor 
melanoma survival.36,40,132 This is a novel finding where combination of the two biomarkers 
Ki67 and D2-40 has been shown to independently and significantly predict SLN metastasis 
and melanoma death in a cohort of melanoma patients. Our study limitations include 
having a single person performing the IHC scoring and the lack of a validation cohort.  
 
In conclusion, we studied a panel of biomarkers including SOX18, Ki67, D2-40, CD31 to 
explore their association with SLN metastasis and melanoma death. Positive SOX18 was 
associated with lower SLN metastasis and melanoma death, opening new avenues to 
explore the role of immune factors and the relationship with different subpopulation of 
endothelial cells. The presence of Ki67+ nuclei in D2-40+ vessels was an independent 
predictor of SLN metastasis and melanoma death, further reinforcing existing knowledge 
on the separate biomarkers Ki67 and D2-40, but is a novel finding as a combination 
biomarker in a cohort of melanoma patients. Most markers used in our study are routinely 
used in pathology laboratories, making their clinical implementation rather feasible. 
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Supplementary materials and methods 
Staining protocol for multiplex panel 
Antibodies:   
1. SOX18 
2. Melanoma 
3. CD31 
4. D2-40 
5. Ki67 
6. DAPI 
 
Protocol: 
1. Dewax slides. Standard dewax protocol (program 3 on the Leica XL stainer) Tissue 
treatment: Xylene: 1x3 min 2x1min, Ethanol: 100% 2x1min, 90% 1 x 1 min, 70% 1 x 
1 min, running water 3 minutes and RO water briefly.  
2. Condition slides with a 10 minutes’ fix in 10% neutral buffered formalin followed by 
a 10-minute wash in running water. 
3. Endogenous peroxidase is quenched by incubating sections in 0.5% hydrogen 
peroxide in TBS buffer for 5 minutes. 
4. Wash slides with distilled water. 
5. Place slides in 250ml 1X Biocare Medical DIVA Retrieval Buffer (Diva 10X 
DV2004MX) and microwave (LG microwave MS2540SR 1250W) for 2 minutes 20 
seconds with 100% power and then continuing boil for 15 minutes with 20% power.  
On completion remove container of slides and allow to cool for a further 20 minutes 
on the bench.  
6. Wash slides in TBS (Tris Base/NaCl pH7.6) plus 0.025% Tween 20 (Sigma - 
P1379-4L) (TBSTW) 3 x 1minute. 
7. Cover tissue with blocking solution, Biocare Medical Background Sniper (BIC-BS96MM) 
+ 2% BSA (Sigma A7906-100G) for 10 min. 
8. Aspirate blocking solution and add primary antibody anti-Sox18 diluted 1:1000 in 
Biocare Medical Da Vinci Green PBS pH7.3 (PD900 M) to each slide for 60 minutes 
at room temperature.   
9. Wash slides in TBSTW for 3 x 2minutes. 
10. Incubate tissue with Biocare Medical Mach2 anti-Mouse HRP Polymer (BIC-
MHRP520L) for 30 minutes. 
11. Wash slides with TBSTW 3x 2 minutes. 
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12. Cover slides with TSA-OPAL 620(1:100) (Perkin Elmer - FP1495A) for 10 min.   
13. Wash slides with TBSTW 3x 2 minutes. 
14. Rinse slides with distilled water. 
15. Place slides in 250ml 1X Biocare Medical DIVA Retrieval Buffer (Diva 10X 
DV2004MX) and microwave (LG microwave MS2540SR 1250W) for 2 minutes 20 
seconds with 100% power and then continuing boil for 15 minutes with 20% power.  
On completion remove container of slides and allow to cool for a further 20 minutes 
on the bench.  
16. Wash slides in TBS plus 0.025% Tween 20 (TBSTW) 3 x 1minute. 
17. Cover tissue with blocking solution, Biocare Medical Background Sniper (BIC-BS96MM) 
+ 2% BSA (Sigma A7906-100G) for 10 min. 
18. Aspirate blocking solution and add primary antibody, mouse anti-Melanoma (Abcam 
- ab732) diluted 1:1400 in Biocare Medical Da Vinci Green PBS pH7.3 (PD900 M) 
to each slide for 30 minutes at room temperature.   
19. Wash slides in TBSTW for 3 x 2minutes. 
20. Incubate tissue with Perkin Elmer HRP conjugated Goat anti-Mouse (NEF22001EA) 
diluted 1:1000 in TBSTW for 15 minutes. 
21. Wash slides with TBSTW 3x 2 minutes. 
22. Cover slides with TSA-OPAL 690(1:100) (Perkin Elmer - FP1497001KT) for 10 min.   
23. Wash slides with TBSTW 3x 2 minutes. 
24. Rinse slides with distilled water. 
25. Place slides in 250ml 1X Biocare Medical DIVA Retrieval Buffer (Diva 10X 
DV2004MX) and microwave (LG microwave MS2540SR 1250W) for 2 minutes 20 
seconds with 100% power and then continuing boil for 15 minutes with 20% power.  
On completion remove container of slides and allow to cool for a further 20 minutes 
on the bench.  
26. Wash slides in TBSTW 3 x 1 minute. 
27. Cover tissue with blocking solution, Biocare Medical Background Sniper (BIC-BS96MM) 
+ 2% BSA (Sigma A7906-100G) for 10 min. 
28. Aspirate blocking solution and add primary antibody, anti-CD31 diluted 1:400 in 
Biocare Medical Da Vinci green PBS pH7.3 (PD900 M) to each slide for 60 minutes 
at room temperature.   
29. Wash slides in TBSTW for 3 x 2minutes. 
30. Incubate tissue with Perkin Elmer HRP conjugated Goat anti-Mouse (NEF22001EA) 
diluted 1:500 in TBSTW for 20 minutes. 
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31. Wash slides with TBSTW 3x 2 minutes. 
32. Cover slides with TSA-OPAL 570(1:100) (Perkin Elmer - FP1488A) for 15 min.   
33. Wash slides with TBSTW 3x 2 minutes. 
34. Rinse slides with distilled water. 
35. Place slides in 250ml 1X Biocare Medical DIVA Retrieval Buffer (Diva 10X 
DV2004MX) and microwave (LG microwave MS2540SR 1250W) for 2 minutes 20 
seconds with 100% power and then continuing boil for 15 minutes with 20% power.  
On completion remove container of slides and allow to cool for a further 20 minutes 
on the bench.  
36. Wash slides in TBSTW 3 x 1 minute. 
37. Cover tissue with blocking solution, Biocare Medical Background Sniper (BIC-BS96MM) 
+ 2% BSA (Sigma A7906-100G) for 10 min. 
38. Aspirate blocking solution and add primary antibody, mouse anti-D2-40 (Biocare 
Medical - CM266A) diluted 1:800 in Biocare Medical Van Gough yellow PBS pH6.0 
(PD902 M) to each slide for 60 minutes at room temperature.   
39. Wash slides in TBSTW for 3x 2minutes 
40. Incubate tissue with Perkin Elmer HRP conjugated Goat anti-Mouse (NEF22001EA) 
diluted 1:1000 in TBSTW for 30 minutes. 
41. Wash slides with TBSTW 3x 2 minutes. 
42. Cover slides with TSA-OPAL 650 (1:100) (Perkin Elmer - FP1496A) for 10 min.   
43. Wash slides with TBSTW 3x 2 minutes. 
44. Rinse slides with distilled water. 
45. Place slides in 250ml 1X DAKO Target Retrieval Solution Citrate pH6.0 (10X 
S169984-2) and heat retrieve in a Biocare Medical Decloaking Chamber (DC2002) 
programmed to run for 5 minutes at 125oC then cool to 90 oC. On completion 
remove container of slides and allow to cool for a further 20 minutes on the bench.  
46. Wash slides in TBSTW 3 x 1 minute. 
47. Cover tissue with blocking solution, Biocare Medical Background Sniper + 2% BSA for 
10 min. 
48. Aspirate blocking solution and add primary antibody, mouse anti-Ki67 (DAKO - 
M7240) diluted 1:1400 in Biocare Medical Van Gough yellow PBS pH6.0 (PD902 M) 
to each slide for 45 minutes at room temperature.   
49. Wash slides in TBSTW for 3 x 2minutes. 
50. Incubate tissue with Perkin Elmer Opal Polymer HRP (ARH1001EA) for 20 minutes. 
51. Wash slides with TBSTW 3x 2 minutes. 
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52. Cover slides with TSA-OPAL 520 (1:50) (Perkin Elmer - FP1487A) for 10 min.   
53. Wash slides with TBSTW 3x 2 minutes. 
54. Rinse slides with distilled water. 
55. Transfer slides to 250ml citrate pH6.0 stripping buffer and microwave (LG 
microwave MS2540SR 1250W) for 2 minutes 20 seconds with 100% power and 
then continuing boil for 15 minutes with 20% power.  On completion remove 
container of slides and allow to cool for a further 20 minutes on the bench. 
56. Wash slides with 1x TBSTw for 2x 3min. 
57. Counterstain sections with DAPI (5mg/ml stock diluted 1:35000 in TBS pH7.6) for 2 
min. 
58. Rinse slides twice with 1xTBS. 
59. Coverslip with Dako Fluorescent Mounting Medium (S3023). 
60. Take to Vectra Imaging system for scanning. 
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Chapter 5: 
Discussion and conclusion 
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Key findings  
Overall, this study aimed to identify prognostic factors that could better inform melanoma 
prognosis beyond the current staging system. One of the challenges in melanoma is to 
accurately predict tumour behaviour and progression. In a study of 583 patients with 
melanoma less than 0.76mm thickness and without metastases by Slingluff et al133, 4.8% 
progressed to metastatic disease after a mean follow-up of 3.6 years. Early stage 
melanoma can usually can be cured by complete surgical resection while patients with 
advanced melanoma typically require surgical resection and targeted or immunotherapy, 
with rather poor overall prognosis despite recent advancement in therapies. Therefore, it 
would be ideal if we are able to identify patients with thin melanoma that are at risk of 
progressing to metastatic disease at the time of diagnosis, to be able to intervene and 
prevent this progression. Although SLNB is a powerful prognostic tool, it has specific 
limitations, with significant morbidity and costs associated. Tumour-associated biomarkers 
are thought to have great potential in identifying early stage melanoma patients who are 
likely to develop advanced disease and therefore would potentially benefit from adjuvant 
therapy. By doing this study, we aimed to identify promising biomarkers that could warrant 
further large-scale studies and eventually be translated into clinical practice. We also 
investigated the association between having multiple invasive melanomas and survival 
outcome, with the hope that it will provide better prognostication for patients and guide 
melanoma surveillance in these selected patient population.  
 
Chapter two examined the role of a previous primary invasive melanoma as an additional 
criterion beyond TNM-based melanoma staging by investigating its association with SLN 
invasion. One area that was lacking in the published literature was the effect of previous 
invasive melanoma on SLN metastasis of subsequent invasive melanoma. We explored 
this and found additional stage II melanoma was an independent and significant predictor 
of SLN metastasis. We also found association between additional stage II melanoma and 
poorer melanoma-specific survival, which was not found in those with additional stage I 
melanoma, consistent with findings from current literature.  
 
Chapters three and four investigated protein biomarkers that reflect tumour immune 
response and vascularisation to gain insight into the disease behaviour that may predict 
melanoma outcome. In chapter three, we assessed STAT5 expression and found it was a 
protective factor, showing independent and inverse association with melanoma-specific 
death and recurrence. In chapter four, we assessed SOX18 and proliferation (Ki67) in the 
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endothelial cells of lymphatic and blood vessels as determined by vessels positively 
stained by CD31 and D2-40, and studied their association with SLN status and melanoma 
survival. Ki67+ nuclei in D2-40+ vessels reflecting proliferative lymphatic vessels was an 
independent predictor of SLN metastasis and melanoma death. SOX18+ nuclei in CD31+ 
and D2-40+ vessels tended to be associated with better outcomes. This confirms 
melanoma vascularisation can predict tumour and patient outcomes.  
 
Our melanoma tissue samples comprised of whole-section slides and formalin-fixed, 
paraffin-embedded blocks collected between 1994-2011. Given the age of these samples, 
there were some variability in staining quality. We mitigated this issue by excluding 
patients whom tissue samples were of very poor staining quality, and also implemented 
manual scoring method as described below.   
 
Commercially available systems providing automated analysis and scoring of  
digitalised slide images have been widely used to classify diseased tissue areas and  
quantify IHC staining.134-135 Given the heterogeneous nature of our tumour samples and  
problems with some of the tissue sample quality which ultimately affected the  
staining quality, implementing an automated analysis and scoring system was  
slightly time consuming but more importantly, rather inaccurate. Manual scoring was  
performed to achieve better results. Areas of interest or hotspots within each whole slide  
section were selected for IHC scoring.  This method of recognition of candidate hotspots  
could be somewhat subjective. To overcome this potential bias, multiple hotspots were  
selected for each whole slide section and the average and total scores from these  
hotspots were then used for statistical analysis.  
 
 
Clinical implications 
Our findings where patients with multiple invasive melanomas of at least the same stage 
have higher risk of SLN metastasis and melanoma death pose substantial implications in 
clinical practice.  All patients should be encouraged to do regular self-examination, 
especially patients with a past history of invasive melanoma.136 Patients with multiple 
invasive melanomas should be educated on their increased risk of having subsequent 
invasive melanomas, SLN metastasis, and the importance of early detection and treatment 
in improving survival. In addition to recognising new or changing lesions on their skin, they 
should also be taught to examine the draining lymph node sites for any lumps.  It is 
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important that clinicians obtain a thorough history of patient’s past melanoma diagnoses 
and take that into account when devising a follow-up plan. These high-risk patients would 
benefit from more frequent monitoring and any clinical suspicions should certainly trigger 
prompt investigations to detect disease progression sooner rather than later. 
 
An ideal biomarker is one that is measurable and rapidly analysable in the tumour cell, 
sensitive, specific, cost effective, ideally non-invasive and should add value to current 
system. Our panel of biomarkers included CD31, D2-40, Ki67, SOX18, STAT5, p16 and 
CD163, all of which could be made accessible in pathology laboratories and tested on 
tumour tissue at the time of diagnosis. This prevents having to subject patients to further 
invasive procedures. Although we have some promising results, proper validation of these 
biomarkers in independent patient cohorts is needed to interrogate the behaviour of these 
biomarkers and allow further understanding of the molecular basis and function of these 
biomarkers. The discovery of new prognostic biomarkers could potentially guide patient 
selection for SLNB, replace SLNB in patients who are deemed not suitable to undergo the 
procedure, or used in conjunction with SLNB to select appropriate high-risk patients for 
adjuvant therapy. This study is a small step forward in the direction of improving risk 
stratification in melanoma patients.  
 
Our study demonstrated investigations that can be easily implemented in existing 
histopathology routines and therefore is readily accessible to the broader community. 
Despite certain limitations such as a small study cohort, in general they are feasible tests 
that can be used in the general population. 
 
 
Conclusion  
In conclusion, we investigated clinical and protein factors in a cohort of melanoma patients 
to determine if any relationship with melanoma outcome exists. We made novel discovery 
in the pattern of melanoma progression in terms of sentinel lymph node metastasis in 
patients with multiple invasive melanomas. We also gained insight into the role of immune 
activation and tumour vascularisation in melanoma progression and their ability to predict 
tumour and patient outcome. This study forms the basis for further research with the hopes 
to ultimately improve patient outcome.  
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